Document:

EX-10.17

 Exhibit 10.17 

EMPLOYMENT AGREEMENT 
 This
EMPLOYMENT AGREEMENT (“Agreement”) is made this 24th day of November 2013 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc. (“Company”) on the one hand and
James Dentzer (the “Executive”) on the other hand. 
 WHEREAS the Company desires to employ the Executive and the Executive
desires to be employed by the Company, on terms set forth herein; 
 NOW, THEREFORE, in consideration of the mutual agreements set forth
herein, the parties agree as follows: 
 1. Term of Employment. The Executive’s employment under this Agreement shall commence
on December 9, 2013 (the “Start Date”) and shall end on such date as the Executive’s employment terminates in accordance with Section 4 of this Agreement. Subject to the balance of this Agreement, the Executive shall be an
at-will employee of the Company whose employment may be terminated (by the Company or by the Executive) at any time, with or without cause, for any or no reason, in which case the Executive will be entitled to the separation benefits set forth in
Section 4, below. 
 2. Duties. The Executive shall initially have the title of Chief Financial Officer. The Executive
shall devote his full business time and effort to the performance of his duties for the Company, which he shall perform faithfully, to the best of his ability. The Executive shall have all of the customary powers and duties associated with his
position and shall be subject to the Company’s policies, procedures, and approval practices, as generally in effect from time to time for all senior executives of the Company and the direction and oversight of the Company’s Board of
Directors (the “Board”). The Executive will report directly to the President and CEO of the Company. 
 3. Compensation and
Related Matters. 
 a. Base Salary. The Company shall pay the Executive base salary at a rate of $13,958.33 paid twice monthly
(which annualizes to $335,000 less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior
executives. 
 b. Bonus. 

i. Signing Bonus. The Company shall pay the Executive a one-time Signing Bonus of $90,000, less applicable withholdings,
in two equal installments. The first installment shall be made within the first fifteen (15) days of the Executive’s Start Date. The second installment shall be paid within fifteen (15) days of the semi-anniversary of the
Executive’s Start Date (ie., six (6) months after the Start Date) and is contingent on the Executive being employed with the Company as described at the end of this paragraph. The Signing Bonus is subject to the following repayment
obligation: As a condition of the Executive’s employment with the Company and for receiving the Signing Bonus, the 

 
Executive agrees that if, at any time during the twelve months following Start Date, the Executive (a) resigns his employment with the Company for any reason other than as provided for in
Section 4.b. and/or Section 4.e.iv. below, the Executive shall repay the Signing Bonus, less applicable withholdings deducted, to the Company on a pro-rated basis based on length of service; or (b) the Company terminates his
employment for Cause (as defined below), the Executive shall repay the Signing Bonus, less applicable withholdings deducted, to the Company, and in all cases specifically authorizes the Company to deduct all of the Signing Bonus required to be
repaid under this Agreement from his last paycheck and to the extent that there is a balance still owed by the Executive, the Executive will provide payment of such balance within thirty days (30) of his last date of employment. The Executive
will not be deemed to have earned the Signing Bonus, or an installment thereof, if, for any reason, the Executive is not employed by the Company or if the Executive has given notice of termination or been notified of his termination at the time such
Signing Bonus is to be paid. 
 ii. Annual bonus. The Executive shall be eligible to be considered for an Annual Bonus
upon achieving certain pre-determined performance targets consistent with any Incentive Compensation Plan established by the Board. The Annual Bonus shall be based, in part, on the Executive’s performance. The grant of such a bonus shall be in
the sole discretion of the Board. The maximum bonus amount for which the Executive will be eligible is thirty-five percent (35%) of base salary earned for the calendar year. The Annual Bonus will be earned only after it has been granted by the
Board. The Annual Bonus shall be paid to the Executive following the close of the fiscal year to which it relates, in no event later than March 15th of the calendar year immediately following
the calendar year in which it was earned. The Executive must be actively employed by the Company at the time the Board considers granting of bonuses to be eligible to receive such bonus. 

c. Stock/Stock Options. The Executive will receive, pursuant to the Company’s 2010 Employee, Director and Consultant Equity
Incentive Plan (the “Plan”), an incentive stock option grant (the “ISO Grant”) to purchase up to 156,250 shares of Common Stock (equivalent to 1.25% of the Company on a fully-diluted basis as of the Effective Date) at an exercise
price equal to the fair market value of each share on the date of grant as determined by the Board in its sole discretion. The ISO Grant shall vest in accordance with the following scheduling: 25% of the shares underlying the ISO Grant will vest on
the twelve (12) month anniversary of Executive’s Start Date with the Company and the remaining shares will vest and become exercisable on a pro rata, monthly basis, over the subsequent 36 months, beginning with the month after the twelve
(12) month anniversary of the Start Date. Vesting of the ISO Grant will be subject to Executive’s continued status as a service provider with the Company at each such vesting period. The ISO Grant will be subject to the terms of the Plan
and a Stock Option Agreement that the Company and Executive will be required to execute (the “Option Agreement”). The ISO Grant will fully accelerate upon Change of Control of the Company as defined in herein. 

d. Benefits. During his employment with the Company, the Executive shall be entitled to participate in all employee benefit plans and
programs, including paid sick leave and holidays, life insurance, disability, medical, dental, and retirement savings plans, to the same 

  
 - 2 - 

 
extent generally available to senior executives of the Company, in accordance with the terms of those plans and programs. The Executive shall be permitted up to four weeks of paid vacation per
year, which will accrue on a monthly basis. The Executive will not be allowed to accumulate more than three weeks of unused vacation days at any given time. The Executive may carry over a maximum of five unused vacation days from one calendar year
to the next. 
 e. Expenses. The Company agrees to reimburse the Executive for reasonable out-of-pocket expenses incurred in
connection with Company business and within standards to be established by the Board from time to time, including, without limitation, travel and accommodations for authorized business trips, provided vouchers therefore, or other supporting
information as the Company may reasonably require, are presented to the Company. All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A of the Internal Revenue Code and the
rules and regulations thereunder (“Section 409A”) including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in
this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year; (iii) the reimbursement of an eligible expense shall be made
no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit. 

4. Termination 
 a.
Rights and Duties. The Executive is an employee “at will.” Accordingly, the Company or the Executive may terminate his employment, at any time with or without cause, for any lawful reason, or no reason. The Executive and the Company
agree that, without modifying or altering the Executive’s “at will” status, each will provide the other with at least thirty (30) days’ prior written notice of termination of the Executive’s employment with the Company.
If the Executive gives notice of termination, except in the case of a termination by the Executive for “Good Reason” as set forth below, such notice will be deemed a voluntary resignation by the Executive and the Company, in its sole
discretion, may elect to relieve the Executive of any obligation to perform duties during the notice period, waive the notice period and immediately accept termination of the Executive’s employment, without changing the status of such
termination as a voluntary resignation by the Executive. Should the Company in the event of a voluntary resignation decide to relieve the Executive of any obligation to perform duties during the notice period, waive the notice period and immediately
accept termination of the Executive’s employment, it shall nonetheless continue his compensation and benefits for the term of the notice period, except that no bonus shall be earned or awarded during and after the notice period. 

b. Termination for “Good Reason.” The Executive may terminate his employment at any time for “Good Reason.”
“Good Reason” shall comport with the requirements of Regulation §1.409A-1(n)(ii) and shall mean: 
 i.
A material diminution in the Executive’s authority, duties or responsibilities; 

  
 - 3 - 

 ii. A material diminution by the Company of the Executive’s annual
base compensation then in effect, except a material diminution generally affecting the members of the Company’s management; 

iii. Any action or inaction by the Company that constitutes a material breach by the Company of the terms of this
Agreement; or 
 iv. A requirement that the Executive be based more than 50 miles from the offices at which he was
principally employed immediately prior to the date of termination. 
 The parties acknowledge and agree that “Good Reason” shall
not be deemed to have occurred unless: (1) the Executive provides the Company with written notice that he intends to terminate his employment hereunder for one of the Good Reason grounds set forth in Section 4.b. within sixty
(60) days of the initial occurrence of such ground, with such notice containing a description of such ground, (2) if such Good Reason ground is capable of being cured, the Company has failed to cure such ground within a period of thirty
(30) days from the date of such written notice, and (3) the Executive terminates his employment within ninety-one (91) days from the date that such Good Reason ground first occurs. For purposes of clarification, the above-listed
conditions shall apply separately to each occurrence of a Good Reason ground, and failure to adhere to such conditions in the event of the occurrence of grounds that would otherwise have constituted Good Reason had the conditions herein been
satisfied shall not disqualify the Executive from asserting and satisfying the conditions for Good Reason for any subsequent occurrence that may constitute Good Reason. 

c. Termination by the Company for Cause. The Company may terminate the Executive’s employment at any time for “Cause.”
“Cause” shall mean: 
 i. The Executive’s commission of an act of fraud, dishonesty, breach of
fiduciary duty or misappropriation which may or does adversely affect the Company; 
 ii. The Executive’s
conviction or plea of guilty or nolo contendere to or engaging in any felony or crime involving moral turpitude, fraud, misrepresentation or other crime and/or indictment for a crime that, in the reasonable opinion of the Company, affects the
Executive’s ability to perform the duties set forth in this Agreement and/or reflects negatively upon the Company; 

iii. Unauthorized disclosure by the Executive of the Company’s Proprietary Information, as defined in the
Nondisclosure Agreement (as defined in Section 5 below) which results or could have been reasonably foreseen to result, in a material financial loss to the Company; or 

iv. The Executive’s material breach of this Agreement or the Nondisclosure Agreement. If such breach is reasonably
possible of being cured in the opinion of the Company, then the Executive will be given thirty (30) days after written notice from the Company of such breach to cure. 

v. The Executive’s failure (which shall not include any Disability as defined below) or refusal to perform the
duties and responsibilities of his employment and/or to follow the policies and procedures of the Company, including without limitation the failure or refusal to carry out lawful instructions from the Board. If such failure or refusal is reasonably
possible of being cured in the opinion of the Company, then the Executive will be given thirty (30) days after written notice from the Company of such failure or refusal to cure. 

  
 - 4 - 

 d. Termination in the Event of Death or Disability. The Agreement shall terminate upon the
Executive’s death or Disability, and the Executive’s employment with the Company shall thereupon terminate. For purposes of the Agreement, “Disability” is defined as any illness, injury, accident or condition of either a physical
or psychological nature as a result of which the Executive is unable to perform the essential functions of his duties and responsibilities hereunder for 90 days during any period of 365 consecutive calendar days or for any consecutive 90-day period.

 e. Effect of Termination. 

i. If the Executive is terminated by the Company for Cause, or by the Executive voluntarily other than for Good Reason,
then the Executive will only be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment. 

ii. If the Executive’s employment is terminated by the Company other than for Cause, or by the Company due to the
Executive’s Disability, or by the Executive for Good Reason (each of which will be deemed an involuntary termination), then the Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days
accrued prior to termination of employment and, in exchange for the Executive’s execution of a separation agreement and general release provided by the Company and expressly subject to the conditions described in Section 4.e.v. below, the
following: 
 a) Continuation of the Executive’s base salary at the rate in effect as of the day immediately
preceding his date of termination for a six (6) month period, payable in accordance with the Company’s regular payroll practices, less applicable withholdings, commencing at the conclusion of the Review Period (as described below),
provided that the first installment of such payments shall include all amounts which would have been paid during the period between the Executive’s date of termination and the date of such first installment; and 

b) The Executive shall be eligible to continue health benefits pursuant to COBRA or the appropriate state equivalent. If
the Executive is eligible for and properly elects continuation of such coverage during the permissible time frame, the Company will pay the premiums for such group health insurance coverage for the shorter of (i) six (6) months or
(ii) until the Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of such group health insurance coverage. 

  
 - 5 - 

 iii. If the Agreement is terminated because of the Executive’s death,
the Company shall pay to the estate of the Executive the salary and benefits which would otherwise have been payable to the Executive up to the date of termination of his employment because of death. 

iv. In the event a Change of Control (as defined below) occurs and, if within one (1) year thereafter, the
Executive’s employment is terminated by the Company other than for Cause, or by the Company due to the Executive’s Disability, or by the Executive for Good Reason (each of which will be deemed an involuntary termination), then the
Executive will be entitled to payment when due of any unpaid base salary, expense reimbursements, and vacation days accrued prior to termination of employment and, in exchange for the Executive’s execution of a separation agreement and general
release provided by the Company and expressly subject to the conditions described in Section 4.e.v. below, the following: 

a) A lump sum payment equal to one (1) year of the Executive’s base salary at the rate in effect as of the day
immediately preceding his date of termination, less applicable withholdings, commencing at the conclusion of the Review Period (as described below); and 

b) The Executive shall be eligible to continue health benefits pursuant to COBRA or the appropriate state equivalent. If
the Executive is eligible for and properly elects continuation of such coverage during the permissible time frame, the Company will pay the premiums for such group health insurance coverage for the shorter of (i) twelve (12) months or
(ii) until the Executive becomes eligible for health benefits through another employer or otherwise. After the shorter period, the Executive will be responsible for premium payments for continuation of such group health insurance coverage. 

For purposes of this Agreement, “Change of Control” means (A) the occurrence of a merger or consolidation of the
Company whether or not approved by the Board, other than (i) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or
by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation
outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation which is in effect a financing transaction for the Company, including, but not limited to, a reverse merger of the Company into a publicly traded
“shell” company, or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, provided that, in any case, “Change of
Control” shall be in accordance with Regulation §1.409A-3(i)(5)(v). 

  
 - 6 - 

 v. Payment of the severance pay and benefits described in
Section 4.e.ii. or 4.e.iv., as applicable, is expressly conditioned on the Executive’s execution without revocation of the separation agreement and general release described therein, and will commence immediately following a sixty
(60) day period following the effective date of the Executive’s separation from service from the Company (the “Review Period”). The separation agreement and general release will be provided to the Executive on or before the fifth
(5th) day following such separation from service. If the Executive fails or refuses to return such agreement within the Review Period, the applicable severance payments and benefits will be
forfeited. If the Executive is eligible for the severance pay and benefits described in Section 4.e.ii., then he shall not be eligible for and shall not receive the severance pay and benefits described in Section 4.e.iv. Similarly, if the
Executive is eligible for the severance pay and benefits described in Section 4.e.iv., then he shall not be eligible for and shall not receive the severance pay and benefits described in Section 4.e.ii. 

5. Nondisclosure, Noncompetition, Nonsolicitation and Inventions. As a condition of the Executive’s employment by the Company and
the payment of compensation and receipt of benefits referred to above, the Executive agrees to execute the attached standard Employee Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement, in the form attached hereto as Exhibit A
(the “Nondisclosure Agreement”). The Executive acknowledges that the Company would not offer him employment or provide compensation and/or benefits set forth above if he was not willing to be bound by the terms of such Agreement. 

6. Notice. 
 a. To the
Company. The Executive will send all communications to the Company in writing, addressed as follows (or in any other manner the Company notifies him to use): 
  

					
		 		  	 Douglas M. Fambrough, Ph.D.
 President and
CEO
 Dicerna Pharmaceuticals, Inc.
 480 Arsenal Street

Building 1, Suite 120
 Watertown, MA 02472

			
		 	With a copy to:	  	 Sam Zucker
 O’Melveny & Myers
LLP
 2765 Sand Hill Road
 Menlo Park, CA 94025

 b. To the Executive. All communications from the Company to the Executive relating to this Agreement
shall be sent to the Executive in writing, addressed as follows (or in any other manner he notifies the Company to use): 
  

							
		 		  	  

 

 
	  	
				
		 	With a copy to:	  	  

 

 
	  	

  
 - 7 - 

 c. Time Notice Deemed Given. Notice shall be deemed to have been given when delivered or,
if earlier (1) three business days after mailing by United States certified or registered mail, return receipt requested, postage prepaid, or (2) faxed with confirmation of delivery, in either case, addressed as required in this section.

 7. Amendment. No provisions of this Agreement may be modified, waived, or discharged except by a written document signed by a
Company officer duly authorized by the Board and the Executive. A waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at any other time in the future. 

8. Choice of Law; Forum Selection. The validity, interpretation, construction, and performance of this Agreement shall be governed by
the laws of the Commonwealth of Massachusetts without regard to its conflicts of laws principles. Any claims or legal actions by one party against the other regarding this Agreement shall be commenced and maintained exclusively in any state or
federal court located in the Commonwealth of Massachusetts, and the parties hereby submit to the jurisdiction and venue of any such court. 

9. Successors. This Agreement shall be binding upon, and shall inure to the benefit of, the Executive and his estate, but the Executive
may not assign or pledge this Agreement or any rights arising under it. Without the Executive’s consent, the Company may assign this Agreement to any affiliate or to a successor to substantially all the business and assets of the Company. 

10. Taxes; Code Sections 409A and 280G. 

a. The Company shall withhold taxes from payments it makes pursuant to this Agreement as it reasonably determines to be required by
applicable law. 
 b. If the benefits set forth in Section 4.e. of this Agreement constitute “non-qualified deferred
compensation” subject to Section 409A, then the following conditions apply to the payment of such benefits: 

i. Any termination of the Executive’s employment triggering payment of benefits under Section 4.e. must
constitute a “separation from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination of the Executive’s
employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by the Executive to the
Company at the time the Executive’s employment terminates), any benefits payable under Section 4.e. that constitute non-qualified deferred 

  
 - 8 - 

 
compensation under Section 409A shall be delayed until after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas.
Reg. §1.409A-1(h). For purposes of clarification, this Section shall not cause any forfeiture of benefits on the Executive’s part, but shall only act as a delay until such time as a “separation from service” occurs. 

ii. If the Executive is a “specified employee” (as that term is used in Section 409A and regulations and
other guidance issued thereunder) on the date his separation from service becomes effective, any benefits payable under Section 4.e. that constitute non-qualified deferred compensation subject to Section 409A shall be delayed until the
earlier of: (A) the business day following the six-month anniversary of the date his separation from service becomes effective, or (B) the date of the Executive’s death, but only to the extent necessary to avoid the adverse tax
consequences and penalties under Section 409A. On the earlier of: (A) the business day following the six-month anniversary of the date his separation from service becomes effective, or (B) the Executive’s death, the Company shall
pay the Executive in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have paid the Executive prior to that date under Section 4.e. 

iii. It is intended that each installment of the payments and benefits provided under Section 4.e. shall be treated
as a separate “payment” for purposes of Section 409A. 
 iv. Neither the Company nor the Executive
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. 

c. Notwithstanding any other provision of this Agreement to the contrary, in the event of any ambiguity in the terms of this Agreement,
such term(s) shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A, or the payment of increased taxes, excise taxes or other penalties under Section 409A. 

d. The parties intend this Agreement to be in compliance with Section 409A. Executive acknowledges and agrees that Company does
not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A.  

e. If any payment or benefit the Executive would receive under this Agreement, when combined with any other payment or benefit
Executive receives pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (i) constitute a “parachute payment” within the meaning of Section 280G the Code; and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full amount of such Payment; or (B) such lesser amount (with cash payments being
reduced before stock option compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes,
and the Excise Tax, results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. 

  
 - 9 - 

 11. Validity. The invalidity or unenforceability of any provision of this Agreement shall
not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 
 12.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument. 

13. Entire Agreement; Prior Agreements. This Agreement, the Stock Option Agreement and the Nondisclosure Agreement, constitutes the
entire agreement among the parties with respect to the subject matter hereof and, unless otherwise provided herein, supersedes all prior agreements, negotiations or understandings, written or oral in respect thereof. 

[REMAINDER OF PAGE INTENTIALLY LEFT BLANK] 

  
 - 10 - 

							
		 		 	DICERNA PHARMACEUTICALS, INC.
			
	Date: November 13, 2013	 		 	 /s/ Douglas Fambrough

		 		 	By:	 	Douglas Fambrough
		 		 	Its:	 	President and CEO
			
		 		 	JAMES E. DENTZER
			
	Date: November 24, 2013	 		 	 /s/ James E. Dentzer

  
 - 11 - 

 EXHIBIT A 

NONDISCLOSURE, NONCOMPETITION, NONSOLICITATION AND INVENTIONS AGREEMENT 

This Nondisclosure, Noncompetition and Assignment Agreement (the “Agreement”) is made by and between Dicerna Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and James Dentzer (the “Employee”), as of November 24, 2013. 
 The
Employee acknowledges that his employment or the continuance of that employment with the Company is contingent upon his agreement to sign and adhere to the provisions of this Agreement. In consideration of the employment or continued employment of
the Employee by the Company, the Employee and the Company agree as follows: 
 1. Duty to Devote Efforts. The Employee understands
that his employment with the Company requires his undivided attention and effort during normal business hours and excluding periods of vacation and sick leave to which he is entitled. As a result, during his employment with the Company, he shall not
engage in any other employment, occupation, consulting or other activity that conflicts with his/her obligations to the Company, whether directly related to the business in which the Company is involved during the term of his employment with the
Company or otherwise. For the avoidance of doubt, the Employee may engage in charitable, civic and educational activities and community affairs, provided that any such activities and affairs do not, in the aggregate, materially interfere with the
proper performance of the Employee’s duties and responsibilities to the Company. 
 2. Noncompetition. The Employee recognizes
and agrees that the Company will suffer irreparable harm in the event that the Employee enters into competition with the Company, either during or following the Employee’s employment with the Company. Therefore, the Employee agrees that while
the Employee is employed by the Company and for a period of one year following the termination or cessation of such employment (the “Restricted Period”), regardless of the reasons, the Employee shall not, directly or indirectly, alone or
as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity, (a) accept employment with any business or entity that is in competition with the products or
services being conceived, designed, created, developed, manufactured, marketed, distributed or sold by the Company, provided that nothing contained in this subsection (a) will prevent the Employee from being employed by a subsidiary,
division, affiliate or unit (each, a “Unit”) of an entity if that Unit is not engaged in any business which is in competition with the products or services being conceived, designed, created, developed, manufactured, marketed, distributed
or sold by the Company, irrespective of whether some other Unit of such entity engages in such competition; (b) engage in or undertake any business operations of conceiving, designing, creating, developing, manufacturing, marketing,
distributing selling or rendering (or assisting any other person in conceiving, designing, creating, developing, manufacturing, marketing, distributing selling or rendering) products or services that are in competition with the products or services
being conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company or (c) invest in or assist in any manner any business which directly or indirectly competes with the business or future business
plans of the Company, except that he may 

  
 - 12 - 

 
own up to one percent (1%) of the outstanding securities of any corporation having a class of equity securities actively traded on a national securities exchange or on the NASDAQ Stock
Market. A business or entity shall be deemed to be in competition with the products or services being conceived, designed, created, developed, manufactured, marketed, distributed, sold or rendered by the Company if it is in the business of
development, manufacture, license, sale and distribution of RNAi-based therapeutic and diagnostic products (including, but not limited to, DsiRNA technology). The geographic scope of this Section 2 shall extend to anywhere the Company is doing
business, has done business or intends to do business. The Employee acknowledges and agrees that if he violates any of the provisions of this Section 2, the Restricted Period will be extended from the date of termination of employment for a
period equal to any period during which he engages in such violation(s), whether such period is during the pendency of litigation or otherwise. 

3. Nonsolicitation of Customers. The Employee recognizes and agrees that the clients, customers and accounts of the Company, which the
Company now or hereafter services during the Employee’s employment with the Company, and all prospective clients, customers and accounts from whom the Employee has solicited business while in the employ of the Company, shall be solely the
clients, customers and accounts of the Company. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of one (1) year following the termination or cessation of such employment, regardless of the
reasons, the Employee shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder, or in any other capacity whatsoever, of any entity, solicit, divert or take away, attempt
to divert or to take away, any client, customer or account of the Company, or any potential client, customer or account of the Company which were contacted, solicited or served by the Employee while employed by the Company or about whom the Employee
obtained or became familiar with through Confidential Information (as defined in Section 5). The geographic scope of this Section 3 shall extend to anywhere the Company is doing business, has done business or intends to do business. 

4. Nonsolicitation of Employees. The Employee recognizes and agrees that the Company has invested substantial resources and effort in
assembling its present staff and personnel. Therefore, the Employee agrees that while the Employee is employed by the Company and for a period of one (1) year following the termination or cessation of such employment, regardless of the reasons,
the Employee shall not, directly or indirectly: (i) recruit, solicit or hire any employee of the Company; or (ii) induce or attempt to induce any employee of the Company to terminate his employment with, or otherwise cease his/her
relationship or engagement with, the Company. 
 5. Nondisclosure. The Employee agrees that all Confidential Information (as defined
below), whether or not disclosed orally or in writing, is and shall be the exclusive property of the Company. The Employee shall not at any time, whether during or after the termination or cessation of his employment, without written authorization
of the Chief Executive Officer of the Company, unless and until the Confidential Information has become public knowledge without fault by the Employee, (a) reveal any Confidential Information to any person or entity, except to employees of the
Company who need to know such Confidential Information for the purposes of their employment, (b) use or attempt to use any Confidential Information for any purposes (other 

  
 - 13 - 

 
than in the ordinary course of performing his duties as an employee of the Company), or (c) use any Confidential Information in any manner which may injure or cause loss or may be calculated
to injure or cause loss to the Company, whether directly or indirectly. The term “Confidential Information” shall include any information concerning the organization, business, business relationships or finances of the Company or of any
third party which the Company is under an obligation to keep confidential or that is maintained by the Company as confidential. Such Confidential Information shall include, but is not limited to, trade secrets or confidential information respecting
inventions, products, designs, methods, know-how, techniques, systems, processes, specifications, blueprints, engineering data, software programs, works of authorship, clinical testing programs, marketing material, customer lists, customer
information, financial information, pricing information, personnel information, business plans or strategy, projects, plans and proposals. 

6. Company Property. 
 a.
The Employee agrees that Company Property (as defined below) shall be and is the exclusive property of the Company to be used by the Employee only in the performance of his duties for the Company and further agrees that during his employment with
the Company, or after the termination or cessation of such employment, he shall not make, use or permit to be used any Company Property otherwise than for the benefit of the Company. All such Company Property or copies thereof and all tangible
property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) upon the termination or cessation of the Employee’s employment. After
such delivery, the Employee shall not retain any such Company Property or copies thereof or any other tangible property. The term “Company Property” shall include all files, letters, notes, memoranda, reports, lists, records, drawings,
sketches, laboratory notebooks, specifications, software programs, software code, data, computers, cellular telephones, pagers, credit and/or calling cards, keys, access cards, documentation or other materials of any nature and in any form, whether
written, photographic, printed, electronic or in digital format or otherwise, relating to any matter within the scope of the business of the Company or concerning any of its dealings or affairs and any other Company property in Employee’s
possession, custody or control. 
 b. The Employee agrees that his obligation not to disclose or to use information and materials of the
types set forth in Section 6(a) above, and his obligation to return materials and tangible property, set forth in Section 6(a) above, also extends to such types of information, materials and tangible property of clients, customers and
accounts of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee. 

7. Assignment of Developments. 

a. If at any time or times during Employee’s employment with the Company or prior to the Employee’s employment with the Company when
working with, for, or on behalf of the Company in a capacity other than as an employee, he did or shall (either alone or with others) make, conceive, create, discover, invent or reduce to practice, whether or not during normal working hours or on
the premises of the Company, any Development that (i) relates to the business 

  
 - 14 - 

 
of the Company or any customer of or supplier to the Company or any of the products or services being developed, manufactured or sold by the Company or which may be used in relation therewith;
(ii) results from tasks assigned to the Employee by the Company; or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for or by the Company, then all such Developments
and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as works made for hire or otherwise. The term “Development” shall mean any invention, modification, discovery, design,
development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable
under copyright, trademark or similar statutes). The Employee shall fully and promptly disclose to the Company (or any persons designated by it) each such Development. To the extent not already owned by the Company, the Employee agrees to assign and
does hereby assign to the Company (or any person or entity designated by the Company) all his right, title and interest (including, but not limited to, rights to inventions, patentable subject matter, copyrights and trademarks) in and to the
Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate, without cost or delay, and without disclosing to others the same, all available information relating
thereto (with all necessary plans and models) to the Company. The Employee also hereby waives all claims to moral rights in any Developments. 

b. Excluded Developments. This Section 7 shall not apply to Developments which do not relate to the present or planned business or
research and development of the Company and which are made and conceived by the Employee not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Confidential Information, but
shall apply to past Developments, including Developments made prior to the Employee’s employment as an employee. The Employee represents that the Developments identified in the Appendix, if any, attached hereto comprise the complete list of all
the Developments that the Employee has made or conceived or otherwise claimed ownership prior to his employment by the Company, which Developments are excluded from this Agreement. The Employee understands that it is only necessary to list the title
of such Developments and the purpose thereof but not details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. 

8. Further Assurances. The Employee agrees to cooperate fully with the Company, both during and after his employment with the Company,
with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments. The Employee shall, during his employment and at
any time thereafter, at the request and cost of the Company, promptly sign, execute, make and do all such deeds, documents, acts and things as the Company and its duly authorized officers may reasonably require: 

a. to apply for, obtain, register and vest in the name of the Company alone (unless the Company otherwise directs) patents, copyrights,
trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to renew and restore the same; and 

b. to defend any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or other proceeding,
petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 

  
 - 15 - 

 The Employee further agrees that if the Company is unable, after reasonable effort, to secure the
Employee’s signature on any such papers, application for patent, copyright, trademark or other analogous protection, or other documents regarding any legal protection relating to a Development, whether because of the Employee’s physical or
mental incapacity or for any other reason whatsoever, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee’s agent and attorney-in-fact, to act for and on his behalf and
stead to execute and file any such papers, application or applications or other documents and to do any and all other lawfully permitted acts to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal
protection thereon with the same legal force and effect as if executed by the Employee. 
 9. Employment At Will. The Employee
understands that this Agreement does not constitute an implied or written employment contract and that his employment with the Company is on an “at-will” basis. Accordingly, the Employee understands that either the Company or the Employee
may terminate Employee’s employment at any time, for any or no reason, with or without prior notice. 
 10. Severability. The
Employee hereby agrees that each provision and the subparts of each provision herein shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other
clauses of the Agreement. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or
provisions shall be construed by the appropriate judicial body by limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. The Employee hereby further agrees that the
language of all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for or against either of the parties. 

11. Amendments; Waiver. Any amendment to or modification of this Agreement, or any waiver of any provision hereof, shall be in writing
and signed by the Company. No delay or omission by the Company in exercising any right under this Agreement or any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of that right or
any subsequent breach of such provision or any other provision hereof. 
 12. Survival. This Agreement shall be effective as of the
date entered below. The Employee’s obligations under this Agreement shall survive the termination or cessation of his employment regardless of the manner of such termination or cessation and shall be binding upon his heirs, executors,
administrators and legal representatives. 

  
 - 16 - 

 13. Assignment. The term “Company” shall include Dicerna Pharmaceuticals, Inc.
and any of its subsidiaries, divisions, or affiliates. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and agreements hereunder shall inure to the benefit of and be enforceable by said
successors or assigns. The Employee may not assign this Agreement. 
 14. Representations. 

a. The Employee hereby represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms
of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his employment with the Company or to refrain from competing, directly or
indirectly, with the business of such previous employer or any other party. The Employee further represents that his performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep
in confidence proprietary information, knowledge or data acquired by the Employee in confidence or in trust prior to his employment with the Company, and the Employee will not disclose to the Company or induce the Company to use any confidential or
proprietary information or material belonging to any previous employer or others. The Employee further represents that he has returned all property and confidential information belonging to all prior employers. To the extent that Employee has
retained any non-confidential and non-proprietary materials and documents of a prior employer, such materials and documents have been disclosed in writing to the Company. 

b. The Employee hereby represents that his employment with the Company, the execution of this Agreement and his performance of all of the
terms of this Agreement do not and will not conflict with or breach the terms of any other agreement by which the Employee is bound (including, but not limited to, to keeping in confidence proprietary information acquired by the Employee in
confidence or in trust prior to his employment by the Company). The Employee further represents that he shall not enter into any agreement, either written or oral, in conflict herewith. 

c. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are
considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement by him/her is likely to cause substantial and irreparable damage to the Company and that in the event of such breach the Company
shall have, in addition to any and all remedies of law, the right to an injunction, specific performance or other equitable relief to prevent the violation of the Employee’s obligations hereunder. The Company may apply for such injunctive
relief in any court of competent jurisdiction without the necessity of posting any bond or other security. 
 15. Governing Law; Forum
Selection Clause. This Agreement and any claims arising out of this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, without application of the conflict of laws principles thereof. Any claims or legal actions by one party against the other shall be commenced and maintained exclusively in any state or federal court located in the Commonwealth of
Massachusetts, and the parties hereby submit to the exclusive jurisdiction and venue of any such court. 

  
 - 17 - 

 16. Entire Agreement. This Agreement and the parties’ Employment Agreement set forth
the complete, sole and entire agreement between the parties on the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered into,
discussed or considered by the parties. The Employee agrees that any change or changes in his duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

THE EMPLOYEE ACKNOWLEDGES THAT HE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.

 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as of the
24th day of November, 2013. 
  

			
	Signature:	 	 /s/ James E. Dentzer

	
	Name (Please Print): James E. Dentzer
	
	Address:

  

			
	ACKNOWLEDGED BY:
	
	DICERNA PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Douglas Fambrough

		
	Name:	 	Douglas Fambrough
		
	Title:	 	CEO

  
 - 18 - 

 APPENDIX – TITLE/PURPOSE OF DEVELOPMENTS 

The following is a complete list of all Developments and the purpose of those Developments: 

 

			
	  
	  	No Developments
		
	  
	  	See Below

 Developments and purpose:EX-10.19

 Exhibit 10.19 

***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
 Execution Copy 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

BETWEEN 
 DICERNA PHARMACEUTICALS,
INC. 
 AND 
 KYOWA HAKKO KIRIN
CO., LTD. 
 December 21, 2009 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	ARTICLE 1	 	 DEFINITIONS
	  	 	2	  
			
	ARTICLE 2	 	 COLLABORATION OVERVIEW AND GOVERNANCE
	  	 	16	  
			
	 2.1
	 	 The Research Collaboration
	  	 	16	  
			
	 2.2
	 	 Research Collaboration Goals
	  	 	16	  
			
	 2.3
	 	 Governance – Joint Steering Committee
	  	 	16	  
			
	 2.4
	 	 Governance – Joint Research Committee
	  	 	18	  
			
	 2.5
	 	 Expiration of Research Collaboration Term
	  	 	19	  
			
	 2.6
	 	 Alliance Managers
	  	 	19	  
			
	 2.7
	 	 Appointment Not an Obligation
	  	 	20	  
			
	ARTICLE 3	 	 THE RESEARCH COLLABORATION
	  	 	20	  
			
	 3.1
	 	 Overview of Research Collaboration
	  	 	20	  
			
	 3.2
	 	 [***] DDS Technology
	  	 	20	  
			
	 3.3
	 	 Research Collaboration Term
	  	 	20	  
			
	 3.4
	 	 Research Collaboration Plans
	  	 	21	  
			
	 3.5
	 	 Funding; Costs of Manufacture
	  	 	21	  
			
	 3.6
	 	 Conduct of Research Collaboration
	  	 	22	  
			
	 3.7
	 	 [***] Technology Transfer
	  	 	24	  
			
	 3.8
	 	 Independent DDS Technology
	  	 	24	  
			
	 3.9
	 	 Research Collaboration Exclusivity
	  	 	25	  
			
	ARTICLE 4	 	 SELECTION OF PROGRAM TARGETS; OPTION RIGHTS
	  	 	25	  
			
	 4.1
	 	 Selection of Program Targets
	  	 	25	  
			
	 4.2
	 	 Designation of Research Compounds
	  	 	26	  
			
	 4.3
	 	 Supply of Proprietary Materials
	  	 	27	  
			
	ARTICLE 5	 	 DEVELOPMENT, COMMERCIALIZATION, MANUFACTURING AND SUPPLY
	  	 	27	  
			
	 5.1
	 	 KHK Development Responsibility
	  	 	27	  
			
	 5.2
	 	 Registrations
	  	 	27	  
			
	 5.3
	 	 Development and Commercialization Plans
	  	 	28	  
			
	 5.4
	 	 Manufacturing
	  	 	28	  
			
	 5.5
	 	 Development and Commercialization Diligence
	  	 	28	  
			
	 5.6
	 	 Compliance
	  	 	28	  
			
	 5.7
	 	 Reports; Information; Updates
	  	 	28	  
			
	 5.8
	 	 Adverse Event Reporting
	  	 	29	  
			
	 5.9
	 	 Co-Promotion Option
	  	 	29	  

  
 i 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

							
	ARTICLE 6	 	 GRANT OF LICENSE RIGHTS
	  	 	30	  
			
	 6.1
	 	 License to KHK
	  	 	30	  
			
	 6.2
	 	 Right to Sublicense
	  	 	31	  
			
	 6.3
	 	 License to DICERNA
	  	 	31	  
			
	 6.4
	 	 License Exclusivity
	  	 	32	  
			
	ARTICLE 7	 	 FINANCIAL PROVISIONS
	  	 	32	  
			
	 7.1
	 	 Upfront Payments
	  	 	32	  
			
	 7.2
	 	 Option Exercise Fees
	  	 	32	  
			
	 7.3
	 	 Lead Transfer Milestone
	  	 	33	  
			
	 7.4
	 	 R&D Milestone Payments
	  	 	33	  
			
	 7.5
	 	 Commercial Milestone Payments
	  	 	34	  
			
	 7.6
	 	 Royalty Payments
	  	 	34	  
			
	 7.7
	 	 Royalty Offsets
	  	 	35	  
			
	 7.8
	 	 Accounting Reports; Payment of Royalty
	  	 	37	  
			
	 7.9
	 	 Audit Rights
	  	 	37	  
			
	 7.10
	 	 Payments
	  	 	38	  
			
	 7.11
	 	 Income Tax Withholding
	  	 	38	  
			
	 7.12
	 	 Foreign Currency Exchange
	  	 	38	  
			
	ARTICLE 8	 	 CONFIDENTIALITY
	  	 	39	  
			
	 8.1
	 	 Nondisclosure and Nonuse Obligations
	  	 	39	  
			
	 8.2
	 	 Permitted Disclosure of Confidential Information
	  	 	39	  
			
	ARTICLE 9	 	 DISCLAIMERS, REPRESENTATIONS, WARRANTIES AND INDEMNIFICATIONS
	  	 	40	  
			
	 9.1
	 	 KHK Representations and Warranties
	  	 	40	  
			
	 9.2
	 	 DICERNA Representations and Warranties
	  	 	42	  
			
	 9.3
	 	 Disclaimer
	  	 	44	  
			
	 9.4
	 	 Responsibility and Control
	  	 	44	  
			
	 9.5
	 	 KHK’s Right to Indemnification
	  	 	44	  
			
	 9.6
	 	 DICERNA’s Right to Indemnification
	  	 	45	  
			
	 9.7
	 	 Indemnification Procedures
	  	 	45	  
			
	 9.8
	 	 Insurance
	  	 	46	  
			
	ARTICLE 10	 	 INTELLECTUAL PROPERTY
	  	 	46	  
			
	 10.1
	 	 Disclosures and Reports
	  	 	46	  
			
	 10.2
	 	 DICERNA Program Technology
	  	 	47	  
			
	 10.3
	 	 KHK Program Technology
	  	 	47	  
			
	 10.4
	 	 Joint Technology and Joint Patent Rights
	  	 	47	  

  
 ii 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

							
	 10.5
	 	 Patent Filing and Prosecution
	  	 	47	  
			
	 10.6
	 	 Infringement Claims Against Third Parties
	  	 	50	  
			
	 10.7
	 	 Defense of Infringement Claims
	  	 	51	  
			
	ARTICLE 11	 	 TERM AND TERMINATION
	  	 	53	  
			
	 11.1
	 	 Term of Research Collaboration
	  	 	53	  
			
	 11.2
	 	 Term of Agreement
	  	 	53	  
			
	 11.3
	 	 Termination During the Research Collaboration Term
	  	 	53	  
			
	 11.4
	 	 Termination for Breach
	  	 	53	  
			
	 11.5
	 	 Termination Upon Insolvency
	  	 	54	  
			
	 11.6
	 	 KHK Termination Without Penalty
	  	 	54	  
			
	 11.7
	 	 DICERNA Termination
	  	 	54	  
			
	 11.8
	 	 Effect of Termination Due to KHK Uncured Breach or KHK Termination Without Cause
	  	 	54	  
			
	 11.9
	 	 Effect of Termination Due to DICERNA Uncured Breach
	  	 	55	  
			
	 11.10
	 	 Surviving Provisions
	  	 	56	  
			
	 11.11
	 	 Limitation of Liability
	  	 	56	  
			
	ARTICLE 12	 	 PUBLICITY
	  	 	56	  
			
	 12.1
	 	 Disclosure of Agreement
	  	 	56	  
			
	 12.2
	 	 Use of Names, Logos or Symbols
	  	 	57	  
			
	 12.3
	 	 Publication
	  	 	57	  
			
	ARTICLE 13	 	 MISCELLANEOUS
	  	 	58	  
			
	 13.1
	 	 Force Majeure
	  	 	58	  
			
	 13.2
	 	 Assignment
	  	 	58	  
			
	 13.3
	 	 Severability
	  	 	58	  
			
	 13.4
	 	 Notices
	  	 	58	  
			
	 13.5
	 	 Dispute Resolution
	  	 	59	  
			
	 13.6
	 	 Choice of Law
	  	 	60	  
			
	 13.7
	 	 Entire Agreement
	  	 	60	  
			
	 13.8
	 	 Headings
	  	 	61	  
			
	 13.9
	 	 Independent Contractors
	  	 	61	  
			
	 13.10
	 	 Further Actions
	  	 	61	  
			
	 13.11
	 	 Special Covenant: City of Hope
	  	 	61	  
			
	 13.12
	 	 Waiver
	  	 	61	  
			
	 13.13
	 	 Jointly Prepared
	  	 	61	  
			
	 13.14
	 	 Purposes and Scope
	  	 	61	  
			
	 13.15
	 	 Counterparts
	  	 	62	  

  
 iii 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 21,
2009 ( the “Effective Date”), by and between DICERNA PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“DICERNA”), and KYOWA HAKKO KIRIN CO. LTD., a
corporation organized and existing under the laws of Japan (“KHK”). 
 RECITALS 

A. DICERNA has proprietary intellectual property, technology, and know-how useful for the discovery, research, development and
commercialization of RNA interference (“RNAi”) therapeutic molecules, including its proprietary Dicer Substrate Technology and Dicer Substrate siRNA and drug delivery systems. 

B. KHK has proprietary intellectual property, technology, and know-how useful for the research, development and commercialization of
therapeutic molecules, including its proprietary [***] (as hereinafter defined) drug delivery technology, and expertise for the conduct of pharmacological in vivo studies for various pharmaceutical products. 

C. KHK and DICERNA wish to establish a collaborative relationship to identify, research, develop and optimize Dicer Substrate siRNA-based
compounds for a specified number of agreed targets and to evaluate the most applicable drug delivery system for use with the initial target, KRAS (as hereinafter defined), in the field of human cancer treatment, for the intended purpose of
proceeding to the development of compounds for the initial target and other agreed targets. 
 D. KHK and DICERNA wish to provide for the
grant to KHK of an option, in the event the results of the research collaboration for the initial target, KRAS, meet agreed criteria, under which KHK may then decide whether to elect to proceed with the further development of KRAS, as well as
research compounds, aimed at such initial target, KRAS and/or to elect to proceed with the development of other research compounds aimed at other agreed targets, in accordance with the terms and conditions set forth herein. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, the Parties agree as follows: 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 ARTICLE 1 

DEFINITIONS 
 Capitalized terms used in
this Agreement, whether in the singular or plural, have the meanings set forth below, or as otherwise specifically defined in this Agreement. 

1.1 “Acceptance” means, with respect to a Drug Approval Application filed for a Licensed Product, (a) in the
United States, the receipt of written notice from the FDA in accordance with 21 CFR 314.101(a)(2) that such Drug Approval Application is officially “filed”; (b) in the European Union, receipt of written notice of acceptance by the
EMEA of such Drug Approval Application for filing under the centralized European procedure in accordance with any feedback received from European Regulatory Authorities; provided, that, if the centralized filing procedure is not used, then
Acceptance shall be determined upon the acceptance of such Drug Approval Application by the applicable Regulatory Authority in any European country; and (c) in Japan, receipt by KHK of written notice of acceptance of filing of such Drug
Approval Application from the Japanese Ministry of Health, Labor and Welfare (“MHLW”). 

1.2 “[***]” shall have the meaning set forth in Section 4.1(c)(ii). 

1.3 “[***]” shall have the meaning set forth in Section 4.1(c)(ii). 

1.4 “Additional Target” shall have the meaning set forth in Section 4.1(c)(i). 

1.5 “Additional Target Notice” shall have the meaning set forth in Section 4.1(c)(i). 

1.6 “Additional Target Option Period” shall have the meaning set forth in Section 4.1(c)(i). 

1.7 “Adverse Event(s)” means any untoward medical occurrence in a patient or clinical investigation subject who is
administered a medicinal product, which occurrence may have, but does not necessarily have to have, a causal relationship with the medicinal product, including any occurrence designated as an adverse event under 21 C.F.R. 312.32 and any other
Applicable Laws. 
 1.8 “Affiliate” means any person, organization, corporation or other business entity that
directly or indirectly controls, is controlled by, or is under common control with a Party hereto. For purposes of this definition, an entity will be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty
percent (50%) of the outstanding stock or other voting rights entitled to elect directors or their equivalent of such other entity. 

  
 2 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.9 “Annual Net Sales” means, with respect to any Calendar Year, the
aggregate amount of the Net Sales for such Calendar Year. 
 1.10 “Applicable Laws” means Federal, state, local,
national and supra-national laws, statutes, rules and regulations, including any rules, regulations or requirements of any Regulatory Authority, national securities exchange or securities listing organization, that are in effect from time to time
during the Term and apply to a particular activity hereunder. 
 1.11 “[***]” shall have the meaning set forth in
Section 7.2.5. 
 1.12 “Calendar Quarter” means the period beginning on the Effective Date and ending on the
last day of the calendar quarter in which the Effective Date falls, and thereafter the respective three month periods ending on March 31, June 30, September 30, or December 31 for so long as this Agreement is in effect.

 1.13 “Calendar Year” means the period beginning on the Effective Date and ending on December 31 of the
calendar year in which the Effective Date falls, and thereafter each successive twelve month period commencing on January 1 and ending on December 31 for so long as this Agreement is in effect. 

1.14 “Challenge” means any challenge to the validity or enforceability of any of the DICERNA Patent
Rights or KHK Patent Rights, including without limitation by (a) filing a declaratory judgment action in which any of the DICERNA Patent Rights or KHK Patent Rights is alleged to be invalid or unenforceable; (b) citing prior art pursuant
to 35 U.S.C. §301, filing a request for re-examination of any of the DICERNA Patent Rights or KHK Patent Rights pursuant to 35 U.S.C. §302 and/or §311, or provoking or becoming party to an interference with an application for any of
the DICERNA Patent Rights or KHK Patent Rights pursuant to 35 U.S.C. §135; or (c) filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against any of the DICERNA Patent Rights or KHK Patent
Rights in any country. 
 1.15 “CMO” means any contract manufacturing organization. 

1.16 “Combination Product” means any pharmaceutical product which includes a Licensed Product and at least one
therapeutically-active compound that is not a Licensed Product, including, for example, an antibody, a low molecular weight compound or other compound that is not a DsiRNA-Based Compound and is not conjugated to a DsiRNA-Based

  
 3 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Compound. For purposes of clarity, two or more DsiRNA-Based Compounds used together as active ingredients in a Nanoparticle DDS for a Licensed Product for a single or multiple Target(s) shall not
constitute a “Combination Product” for purposes of this Agreement. 
 1.17 “Commercially Reasonable
Efforts” means, with respect to a Party’s obligations under this Agreement, [***]. 
 1.18 “Confidential
Information” means (a) with respect to DICERNA, all tangible embodiments of DICERNA Background DDS Technology, DICERNA Background Dicer Substrate Technology and DICERNA Program Technology (b) with respect to KHK, all tangible
embodiments of KHK [***] DDS Technology and KHK Program Technology and (c) with respect to each Party, any and all inventions, Know-How, and data and shall include, without limitation, information relating to research and development plans,
experiments, results and plans, compounds, therapeutic leads, candidates and products, clinical and preclinical data, trade secrets and manufacturing, marketing, financial, regulatory, personnel and other business information and plans, all
scientific, clinical, regulatory, marketing, financial and commercial information or data, whether communicated in writing, orally or by any other means, and which is disclosed or provided by or on behalf of such Party (the
“Disclosing Party”) to the other Party (the “Receiving Party”) in connection with this Agreement. Confidential Information will not include information that: 

(a) is known by the Receiving Party at the time of its receipt, and not through a prior disclosure by the Disclosing Party, as documented by
written records; 
 (b) is properly in the public domain through no fault of the Receiving Party; 

(c) is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality
to the Disclosing Party; or 
 (d) is developed by the Receiving Party independently of Confidential Information received from the
Disclosing Party, as documented by written records. 
 For purposes of clarity, unless excluded from Confidential Information pursuant to (a) through
(d) above, any scientific, technical or financial information of a Party that is disclosed at any meeting of the JSC or JRC or disclosed through an audit report shall constitute Confidential Information of the Disclosing Party. Notwithstanding
anything herein to the contrary, the terms of this Agreement shall constitute Confidential Information of each Party. 
 1.19
“Control” or “Controlled” means, with respect to any Patent Rights or Know-How, that the Party owns or has a license to such Patent Rights or Know-How and has

  
 4 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
the ability to grant access, a license, or a sublicense to such Patent Rights or Know-How to the other Party as provided for in this Agreement without violating an agreement with, or infringing
any rights of, a Third Party as of the time the Party would be first required under this Agreement to grant the other Party such access, license or sublicense. 

1.20 “Co-Promote” or “Co-Promotion” means with respect to any Co-Promoted Product, the joint
promotion and Detailing (as defined in Schedule 7) of such Co-Promoted Product in the Co-Promotion Territory using a coordinated sales force consisting of representatives of both Parties. 

1.21 “Co-Promoted Product” means any Licensed Product for the Initial Target with respect to
which DICERNA has exercised a Co-Promotion Option. 
 1.22 “Co-Promotion Option” shall have the meaning set forth in
Section 5.9(b). 
 1.23 “Co-Promotion Option Exercise Payment” means, with respect to any Co-Promoted Product,
[***]. [***] 
 1.24 “Co-Promotion Option Exercise Period” means, with respect to each Licensed Product for the
Initial Target, the period commencing on [***] and continuing for a period of [***]. 
 1.25 “Co-Promotion
Territory” means the United States of America and its territories and possessions. 
 1.26
“Criteria” means the qualitative and/or quantitative required condition(s) to be used with respect to each DsiRNA-Based Compound for a given Program Target to advance the DsiRNA-Based Compound for such Program Target to the
next stage of the Research Collaboration or development. For purposes of clarity, the Criteria shall be set forth in Schedules 3-A, 3-B and 3-C attached hereto, as amended by mutual agreement of the Parties. 

1.27 “CRO” means any contract research organization. 

1.28 “CTN” means the notification submitted to the Japanese Ministry of Health, Labor and Welfare prior to the
initiation of a clinical trial in Japan. 
 1.29 “DDS” or “Drug Delivery System” means any
excipient, conjugate or formulation designed to improve the pharmacokinetic, pharmacodynamic, biodistribution, and/or other pharmaceutical properties of any DsiRNA-Based Compound and achieve intracellular uptake. 

  
 5 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.30 “DDS Technology” means any Technology that relates to, or
constitutes, any DDS. 
 1.31 “Development and Commercialization Plan” shall have the meaning set
forth in Section 5.3. 
 1.32 “Development Costs” means, with respect to a Licensed Product subject to a
Co-Promotion Option, the External Development Costs and Internal Development Costs incurred by KHK (or for its account by an Affiliate or a Third Party) for the purpose of obtaining Registration in the Co-Promotion Territory after the Effective Date
that are generally consistent with the respective development activities of KHK in the applicable Development and Commercialization Plan and are directly and solely attributable to the development of such Licensed Product. 

1.33 “Development Criteria” means the qualitative and/or quantitative criteria described in Schedule 3-C with
respect to the identification of a Licensed Product. 
 1.34 “DICERNA Background DDS Patent Rights” means any Patent
Rights Controlled by DICERNA as of the Effective Date listed in the attached Schedule 2-A, and any Patent Rights Controlled or owned or controlled by DICERNA during the Term that contain one or more claims that cover DICERNA Background DDS
Technology. For purposes of clarity, attached hereto as Schedule 2-A is a list represented by DICERNA to be a complete and accurate list of patents and patent applications Controlled by DICERNA as of the Effective Date that contain one
or more claims that cover DICERNA DDS Background Technology. For purposes of this definition only, “controlled” means, with respect to any Patent Rights that DICERNA licenses from a Third Party, the ability of DICERNA to grant a
sublicense to such Patent Rights without violating the license agreement with, and without the payment by DICERNA of any additional consideration to, the Third Party licensor. 

1.35 “DICERNA Background DDS Technology” means any Know-How Controlled by DICERNA as of the Effective Date that
relates to any DDS Technology, or owned or controlled by DICERNA during the Term that relates to Nanoparticle DDS. For purposes of clarity, DICERNA Background DDS Technology shall not include DICERNA Program Technology or DICERNA’s interest in
Joint Technology. For purposes of this definition only, “controlled” means, with respect to any Know-How that DICERNA licenses from a Third Party, the ability of DICERNA to grant a sublicense to such Know-How without violating the
license agreement with, and without the payment by DICERNA of any additional consideration to, the Third Party licensor. 

  
 6 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.36 “DICERNA Background Dicer Substrate Patent Rights” means any
Patent Rights Controlled by DICERNA during the Term, including without limitation the Patent Rights licensed by DICERNA from City of Hope under the DICERNA-COH License Agreement, whether filed before or after the Effective Date, other than the
DICERNA KRAS Specific Patent Rights and DICERNA Background DDS Patent Rights, that contain one or more claims that cover DICERNA Background Dicer Substrate Technology. For purposes of clarity, attached hereto as Schedule 2-B is a list
represented by DICERNA to be a complete and accurate list of patents and patent applications Controlled by DICERNA as of the Effective Date that relate to DICERNA Background Dicer Substrate Technology. 

1.37 “DICERNA Background Dicer Substrate Technology” means any Know-How with respect to DICERNA’s Dicer Substrate
platform technology that is Controlled by DICERNA during the Term. For purposes of clarity, DICERNA Background Dicer Substrate Technology shall not include DICERNA Background DDS Technology or DICERNA Program Technology. 

1.38 “DICERNA Cost and Revenue Sharing Percentage” means, with respect to any Co-Promoted Products, fifty percent
(50%). 
 1.39 “DICERNA-COH License Agreement” means that certain Exclusive License Agreement dated as of
September 28, 2007 by and between DICERNA and City of Hope. 
 1.40 “DICERNA KRAS Specific Patent Rights” means
any Patent Rights Controlled by DICERNA during the Term that contain one or more claims that are specific to KRAS. For purposes of clarity, attached hereto as Schedule 2-C is a complete and accurate list of all patents and patent applications
that are specific to KRAS and that are Controlled by DICERNA as of the Effective Date. 
 1.41 “DICERNA Patent
Rights” means, collectively, DICERNA Program Patent Rights, DICERNA Background Dicer Substrate Patent Rights, DICERNA KRAS Specific Patent Rights and, solely to the extent selected for a Research Compound or a Licensed Product pursuant
to Section 6.1, DICERNA Background DDS Patent Rights. 
 1.42 “DICERNA Program Patent Rights” means any Patent
Rights that contain one or more claims that are specific to DICERNA Program Technology. 
 1.43 “DICERNA Program
Technology” means (a) any Program Technology that (i) is not KHK Program Technology and (ii) is conceived or first reduced to practice by employees of, or consultants to, DICERNA, alone or jointly with any Third Party,
without the use in any material respect of any KHK [***] DDS Technology, KHK Patent Rights or Joint Technology; 

  
 7 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
and (b) any Program Technology, regardless of whether conceived or first reduced to practice by employees of, or consultants to, DICERNA, KHK, or jointly by both Parties, that relates to, or
constitutes, DICERNA Background Dicer Substrate Technology or DICERNA Background Dicer Substrate Patent Rights. 
 1.44
“DsiRNA” or “Dicer Substrate siRNA” means any synthetic nucleic acid that is encompassed within DICERNA Background Dicer Substrate Technology and typically includes, but is not limited to, a duplex of
twenty-five (25) base pairs or longer in length and that is processed by the dicer enzyme and mediates gene silencing through the RNAi pathway. 

1.45 “DsiRNA-Based Compound” means a compound that contains or consists of DsiRNA. For purposes of clarity, a
DsiRNA-Based Compound shall include, but is not limited to, any DsiRNA Conjugate and any Nanoparticle DsiRNA Conjugate. 
 1.46
“DsiRNA Conjugate” means a Dicer Substrate that is a conjugate and that is for direct therapeutic administration (i.e., it is modified such that it has appropriate pharmaceutical properties without requiring formulation
within a Nanoparticle DDS). 
 1.47 “Drug Approval Application” means, with respect to a Licensed Product in a
particular country or region, an application for Registration of such Licensed Product in such country or region, including without limitation: (a) an NDA or sNDA; (b) a counterpart of an NDA or sNDA in any country or region in the
Territory (including, without limitation, a CTN in Japan and an MAA in the European Union); and (c) all supplements and amendments to any of the foregoing. 

1.48 “Effective Date” means the date first written above. 

1.49 “EMEA” means the European Medicines Agency or any successor agency or authority thereto. 

1.50 “European Union” or “EU” means
the countries of the European Union, as the European Union is constituted as of the Effective Date and as it may be expanded from time to time. 

1.51 “[***] Target” means the [***] Targets listed in Schedule 5-B attached hereto. 

1.52 “[***] Target Criteria Satisfaction Payment” shall have the meaning set forth in Section
7.2.4. 
 1.53 “[***] Target Exercise Notice” shall have the meaning set forth in Section
4.1(b)(i). 

  
 8 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.54 “[***] Target Payment” shall have the
meaning set forth in Section 7.2.3. 
 1.55 “[***] Target Period” shall have the meaning set forth in Section
4.1(b)(i). 
 1.56 “[***] Option” shall have the meaning set forth in Section 4.1(b)(i). 

1.57 “External Development Costs” means, with respect to a Licensed Product subject to a Co-Promotion Option, [***].

 1.58 “FDA” means the United States Food and Drug Administration or any successor agency having the administrative
authority to regulate the approval for marketing of new human pharmaceutical or biological therapeutic products in the United States. 

1.59 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, as amended. 

1.60 “Field” means, collectively, the Primary Field and the Secondary Field. 

1.61 “First Commercial Sale” means with respect to any Licensed Product in a country in the Territory, the first sale,
transfer or disposition for value of such Licensed Product in such country to a Third Party by KHK, its Affiliates or its Sublicensees. For purposes of clarity, First Commercial Sale shall not include the transfer of reasonable quantities of any
free samples of a Licensed Product or reasonable quantities of a Licensed Product solely for development purposes, such as for use in experimental studies or clinical trials. 

1.62 “GAAP” means United States or Japan or other substantially equivalent generally accepted accounting principles,
consistently applied. 
 1.63 “Generic” means, with respect to a Licensed Product in each country in the Territory,
any DsiRNA-Based Compound that (a) is covered by a claim of any Patent Rights Controlled by either Party (including expired Patent Rights) specific to such Licensed Product in such country and is approved by the applicable Regulatory Authority
in such country for sale in such country; or (b) contains the same active ingredient as such Licensed Product and is approved by the applicable Regulatory Authority in such country for sale in such country; or (c) is approved by the
applicable Regulatory Authority in such country as being the same as the Licensed Product. 
 1.64 “IND” means an
Investigational New Drug application, as defined in 21 C.F.R. 312, and the regulations promulgated thereunder or any successor application authorized by the FDA under the FDCA, as amended from time to time, and any foreign equivalents thereof. 

  
 9 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.65 “Independent DDS Technology” means any DDS Technology Controlled
by either Party as of the Effective Date or during the Term, other than Third Party DDS Technology, and with respect to DICERNA, other than DICERNA Background DDS Technology, and with respect to KHK, other than KHK [***] DDS Technology. 

1.66 “Initial Target” means KRAS. 

1.67 “[***]” shall have the meaning set forth in Section 7.2.2. 

1.68 “[***]” shall have the meaning set forth in Section 4.1(a)(i). 

1.69 “Initial Target Option Payment” shall have the meaning set forth in Section 7.2.1. 

1.70 “Initial Target Option Right” shall have the meaning set forth in Section 4.1(a)(i). 

1.71 “Internal Development Costs” means, with respect to a Licensed Product subject to a Co-Promotion Option, [***].

 1.72 “In Vitro Criteria” means the quantitative criteria described in Schedule 3-B attached hereto
required for the confirmation of a Target as a Program Target. 
 1.73 “In Vivo Criteria” means the qualitative
and/or quantitative criteria described in Schedule 3-A attached hereto with respect to the selection of a Research Compound. 
 1.74
“Joint Patent Rights” means Patent Rights that contain one or more claims that cover Joint Technology. 
 1.75
“Joint Research Committee” or “JRC” means the committee composed of DICERNA and KHK representatives established pursuant to Section 2.4. 

1.76 “Joint Steering Committee” or “JSC” means the committee composed of DICERNA and KHK
representatives established pursuant to Section 2.3. 
 1.77 “Joint Technology” means any Program Technology, other
than DICERNA Program Technology or KHK Program Technology, that is (a) jointly conceived or reduced to practice by employees of, or consultants to, KHK and employees of, or consultants to, DICERNA or (b) conceived or reduced to practice
solely by employees of, or consultants to, a Party through the use in any material respect of any Technology or Patent Rights of the other Party. For purposes of clarity, Joint Technology includes, but is not limited to, data and information
obtained under the Research Collaboration. 

  
 10 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.78 “KHK Background Patent Rights” means any Patent Rights
Controlled by KHK during the Term that contain one or more claims that cover KHK [***] DDS Technology. For purposes of clarity, (a) KHK Background Patent Rights shall not include KHK Program Patent Rights and (b) attached hereto as
Schedule 4 is a complete and accurate list of all KHK Background Patent Rights Controlled by KHK as of the Effective Date. 
 1.79
“KHK Patent Rights” means, collectively, KHK Background Patent Rights and KHK Program Patent Rights. 
 1.80
“KHK Program Patent Rights” means any Patent Rights that contain one or more claims that are specific to KHK Program Technology. 

1.81 “KHK Program Technology” means (a) any Program Technology that (i) is not DICERNA Program Technology
and (ii) is conceived or first reduced to practice by employees of, or consultants to, KHK, alone or jointly with any Third Party, without the use in any material respect of any DICERNA Technology, DICERNA Patent Rights or Joint Technology; and
(b) any Program Technology, regardless of whether conceived or first reduced to practice by employees of, or consultants to, DICERNA, KHK or jointly by both Parties, that relates to or constitutes the KHK [***] DDS Technology and/or KHK
Background Patent Rights. 
 1.82 “KHK [***] DDS Technology” means the Nanoparticle DDS Know-How known
as “[***]” Controlled by KHK. 
 1.83 “Know-How” means all tangible or intangible know-how, inventions
(whether patentable or not), discoveries, processes, formulas, data, clinical and preclinical results, non-patented inventions, trade secrets, and any physical, chemical, or biological material or any replication of any such material in whole or in
part. 
 1.84 “Knowledge” means, with respect to any representation or warranty of DICERNA or
KHK, the actual knowledge of any executive officer (as defined for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of DICERNA or KHK, as the case may be. 

1.85 “KRAS” means the KRAS Gene and its encoded protein including wild type, oncogenic mutant, and alternative spliced
isoforms (K-rasA and K-rasB). 
 1.86 “KRAS Gene” means the gene identified as follows: [***]. 

  
 11 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.87 “Lead Transfer Milestone” shall have the meaning set forth in
Section 7.3. 
 1.88 “Licensed Product” means any pharmaceutical product that KHK decides to develop
that contains, incorporates or is comprised of one or more Research Compounds and that, in any case, targets one or more Program Targets. For purposes of clarity, the term Licensed Product shall include all Co-Promoted Products. 

1.89 “Lipid” means a molecule having both a lipophilic group and a hydrophilic group. 

1.90 “MAA” means an application submitted to the EMEA to obtain European Commission authorization for the marketing of
a Licensed Product in the European Union, or any successor application or procedure required to sell a Licensed Product in the European Union. 

1.91 “Major Market Country” means each of [***]. 

1.92 “[***]” shall have the meaning set forth in Section 4.1(c)(i). 

1.93 “Nanoparticle DDS” means [***]. 

1.94 “Nanoparticle DsiRNA Conjugate” means a DsiRNA that is conjugated to another molecule to improve the
pharmaceutical properties and/or performance of a Nanoparticle DDS. 
 1.95 “NDA” means a new drug application, as
defined in the FDCA and the regulations promulgated thereunder or other applications filed with the FDA to obtain approval for marketing a Licensed Product in the United States, or any future equivalent process and any foreign equivalents thereof.

 1.96 “Net Sales” means, with respect to a Licensed Product, [***]. 

1.97 “Party” means KHK or DICERNA. “Parties” means KHK and DICERNA. 

1.98 “Patent Rights” means the rights and interests in and to: (a) any patent applications (including provisional
applications and applications for certificates of invention); (b) any patents issuing from such patent applications (including certificates of invention); (c) all patents and patent applications based on, corresponding to, or claiming the
priority date(s) of any of the foregoing; (d) any reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecutions, continuations-in-part, or divisions of or to any of the
foregoing; and (e) any term extension or other governmental action which provide exclusive rights beyond the original patent expiration date. 

  
 12 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.99 “Phase II Clinical Trial” means one or more clinical trials
conducted in patients with a particular disease or condition, which clinical trial(s) are designed to establish the safety, appropriate dosage and pharmacological activity of an investigational drug given its intended use, and to initially explore
its efficacy for such disease or condition. 
 1.100 “Phase III Clinical Trial” means one or more clinical trials on
sufficient numbers of patients, which clinical trial(s) are designed to (a) establish that a drug is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the drug in the
dosage range to be prescribed; and (c) support Registration of such drug. 
 1.101 “Primary Field”
means human pharmaceutical use for the treatment of cancer. 
 1.102 “Program Target” means each
Target selected for inclusion in the Research Collaboration. For purposes of clarity, the term Program Target shall mean (a) the Initial Target; (b) any [***] Target with respect to which KHK exercises its [***] Option; (c) [***]; and
(e) [***]. 
 1.103 “Program Technology” means any Know-How (including any new and useful
process, method of manufacture or composition of matter) or Proprietary Material that is conceived and first reduced to practice (actually or constructively), whether or not patentable, by employees of, or consultants to, either Party or jointly by
both Parties, in the conduct of the Research Collaboration or in connection with the development or commercialization of Research Compounds and/or Licensed Products. 

1.104 “Proprietary Materials” means tangible chemical, biological or physical materials (a) that are furnished by
or on behalf of one Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary by the transferring Party or (b) that are otherwise conceived or reduced to practice in the conduct of the
Research Collaboration. 
 1.105 “Royalty Term” shall have the meaning set forth in Section 7.6. 

1.106 “Registration” means, with respect to a Licensed Product, (a) in the United States, approval by the FDA of
an NDA, or similar application for marketing approval, and satisfaction of any related applicable FDA registration and notification requirements (if any), and (b) in any country or region other than the United States, approval by any Regulatory

  
 13 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Authority having jurisdiction over such country or region of a single application or set of applications comparable to an NDA and satisfaction of any related applicable regulatory and
notification requirements, if any, together with any other approval necessary to make and sell pharmaceuticals commercially in such country or region. For purposes of clarity, “Registration” in the United States means
approval of an NDA permitting marketing of the applicable Licensed Product in interstate commerce in the United States, “Registration” in the European Union means marketing authorization for the applicable Licensed Product
pursuant to Council Directive 2001/83/EC, as amended, or Council Regulation 2309/93/EEC, as amended and “Registration” in Japan means final approval of an application submitted to the Ministry of Health, Labor and Welfare
(“MHW”) and the publication of a New Drug Approval Information Package permitting marketing of the applicable Licensed Product in Japan, as any of the foregoing may be amended from time to time. 

1.107 “Regulatory Authority” means the FDA, or any counterpart of the FDA outside the United States, or any other
national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity with authority over the distribution, importation, exportation, manufacture, production, use, storage,
transport, clinical testing or sale of a Licensed Product. 
 1.108 “Research Collaboration” means the program of
research and development of Research Compounds initially for the Initial Target, and if elected by KHK, also for the [***] Targets and [***] Targets [***] as set forth in this Agreement and the Research Collaboration Plan. 

1.109 “Research Collaboration Plan” means each written plan (a) describing the research activities to be carried
out by the Parties during the Research Collaboration Term in conducting the Research Collaboration pursuant to this Agreement, and (b) setting forth all Criteria applicable to each Research Compound that is part of such Research Collaboration.

 1.110 “Research Collaboration Term” shall have the meaning set forth in Section 3.3. 

1.111 “Research Compound” means any DsiRNA-Based Compound that is directed against a Program Target and that is
selected for optimization by KHK as an RNA interference therapeutic molecule as part of the Research Collaboration; provided, that, no DsiRNA-Based Compound shall, after becoming a Waived Compound, be designated or nominated as a Research Compound.

 1.112 “Secondary Field” means human pharmaceutical use for the treatment of [***]. 

  
 14 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 1.113 “Serious Adverse Event” means any untoward medical occurrences
that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly or birth defect. 

1.114 “Sublicensee” means any Third Party or Affiliate to whom KHK grants a sublicense of some or all of the rights
granted to KHK under this Agreement pursuant to Section 6.2 hereof. 
 1.115 “[***]” shall have the meaning set forth in
Section 4.1(b)(ii). 
 1.116 “[***]” shall have the meaning set forth in section 4.1(b)(ii). 

1.117 “Target” means a specific gene and its encoded protein. 

1.118 “Territory” means worldwide. 

1.119 “Third Party” means any Party, other than KHK or DICERNA and their respective Affiliates. 

1.120 “Third Party DDS Technology” means any DDS Technology that is owned or controlled by one or more Third Parties
[***]. 
 1.121 “Unanimous Decision” means any of the following matters requiring the unanimous approval of both KHK
and DICERNA: [***]. 
 1.122 “Valid Claim” means any claim in a pending patent application or an issued and
unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction following exhaustion of all possible appeal processes and which has not been admitted to
be invalid or unenforceable through reissue, reexamination or disclaimer, or otherwise. 
 1.123 “Waived
Compound” means any compound which was once a Research Compound and which is directed against a particular Waived Target. For purposes of clarity, a Research Compound that is directed against a particular Waived Target and is
also directed against any Program Target shall remain a Research Compound until such time as that Program Target becomes a Waived Target. 

1.124 “Waived Target” means any Target that becomes a Waived Target pursuant to Sections 4.1 (a)(ii),
4.1(b)(ii) or 4.1(c)(ii). 

  
 15 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 ARTICLE 2 

COLLABORATION OVERVIEW AND GOVERNANCE 

2.1 The Research Collaboration. DICERNA and KHK agree to undertake the Research Collaboration during the Research
Collaboration Term under the terms and conditions set forth in this Agreement. 
 2.2 Research Collaboration
Goals. The goal of the Parties with respect to the Research Collaboration shall be [***]. The Parties hereby agree that [***].  

2.3 Governance – Joint Steering Committee. 

2.3.1 Establishment. The JSC shall be a forum for the Parties to hold discussions and exchange views regarding the
strategic direction and overall management of the Research Collaboration. The JSC shall consist of [***]. The JSC may name additional members to the JSC from time to time so long as [***]. Each Party will designate a member who will be the primary
contact on the JSC for that Party. Not later than thirty (30) days from the Effective Date (a) DICERNA and KHK shall establish the JSC and (b) each Party shall provide the other with a list of its initial members of the JSC. Not later
than sixty (60) days after the Effective Date, the JSC shall hold an initial organizational meeting. Either Party can change its members on the JSC by written notice to the other Party. 

2.3.2 Joint Steering Committee Meetings. The JSC shall establish a schedule of times for regular meetings; provided, that,
during the Research Collaboration Term the JSC shall meet at least once every [***]. In addition, the JSC may meet on an ad hoc basis on not less than [***] notice (if the meeting is to be conducted in person) or [***] notice (if the meeting is
conducted by teleconference). The Parties shall mutually agree upon the times and places for such meetings, alternating between Watertown, Massachusetts and Tokyo, Japan, or such other location as members of the JSC shall agree. Each Party shall
bear its own costs associated with holding and attending such meetings. If mutually agreed by the Parties, such meetings may be held by videoconference or teleconference. An agenda shall be agreed upon by the JSC members and be distributed to the
Parties by the hosting Party no less than [***] before any meeting. If a representative of a Party on the JSC is unable to attend a meeting of the JSC, such Party may designate an alternate to attend such meeting and vote on behalf of such missing
representative. In addition, each Party may, at its discretion and upon written notice to the other Party, invite nonvoting employees, consultants or advisors (which consultants and advisors shall be under an obligation of confidentiality no less
stringent than those terms set forth herein) to attend any meeting of the JSC. Minutes shall be kept of all JSC meetings by the hosting Party and sent to all members of the JSC for review and approval

  
 16 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
within [***] after each meeting. Minutes shall be deemed approved unless any member of the JSC objects to the accuracy of such minutes by providing written notice to the hosting Party within
[***] of receipt of the minutes; provided, that, in the event of any such objection by a Party that the Parties are unable to resolve, such minutes shall simply reflect such unresolved differences of opinion. 

2.3.3 Joint Steering Committee Responsibilities. The JSC shall, during the Research Collaboration Term, have the
following responsibilities: 
 (a) discussing whether or not to [***] and discussing the allocation between the Parties of the
responsibility for paying any consideration to [***] in connection with such [***], taking into consideration the respective rights of each Party in such [***] DDS Technology; 

(b) periodically reviewing the progress and results of the Research Collaboration to ensure that the Parties are meeting their commitments
for both human and financial support and are each fulfilling all of their respective diligence and other contractual obligations under this Agreement; 

(c) attempting to resolve any disagreements between the Parties with respect to the research conducted under the Research Collaboration,
including any disagreements referred to it by the JRC and any other committee formed by the JSC; 
 (d) reviewing and monitoring all
results of the work performed under the Research Collaboration, including the scientific efforts of both Parties; 
 (e) reviewing and
discussing the Research Collaboration Plans; and 
 (f) discussing such other matters as may be delegated to the JSC pursuant to this
Agreement or by mutual written agreement of the Parties during the Research Collaboration Term. 
 2.3.4 Joint Steering Committee
Decisions. At each JSC meeting, (a) the presence in person of at least [***] shall constitute a quorum and (b) the members of a Party shall have one (1) collective vote on all matters before the JSC at such
meeting. All decisions of the JSC shall be made by unanimous vote. Whenever any action by the JSC is called for hereunder during a time period in which the JSC is not scheduled to meet, any member may cause the JSC to take the action in the
requested time period by calling a special meeting or by circulating a written consent. If the JSC is unable to reach a unanimous vote on any matter, including any matters referred to it for resolution by the JRC (each a “Disputed
Matter”), KHK 

  
 17 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
shall have the right to make the final decision on such Disputed Matter in its sole discretion, provided, that, if the Disputed Matter constitutes a Unanimous Decision, the Disputed Matter shall
be resolved in accordance with Section 13.5. 
 2.3.5 Expiration of Research Collaboration Term. At the expiration
of the Research Collaboration Term, the JSC shall be disbanded and the Parties shall communicate directly with each other with respect to the activities contemplated by this Agreement in such manner as is reasonable and practical, including by
having periodic telephonic and face-to-face meetings as necessary. 
 2.4 Governance – Joint Research
Committee. 
 2.4.1 Establishment. The day to day, working level communications, planning and handling
of practical adjustments of the Research Collaboration shall be performed by the JRC, comprised of equal representation from KHK and DICERNA. The JRC shall consist of [***]. The JRC may name additional members to the JRC from time to time so long as
[***]. Each Party will designate a member who will be the primary contact on the JRC for that Party. Not later than thirty (30) days from the Effective Date (a) DICERNA and KHK shall establish the JRC and (b) each Party shall provide
the other with a list of its initial members of the JRC. Not later than sixty (60) days after the Effective Date, the JRC shall hold an organizational meeting to establish the operational requirements for the JRC. Either Party can change its
members on the JRC by written notice to the other Party.  
 2.4.2 Joint Research Committee Meetings. The JRC
shall establish a schedule of times for regular meetings, taking into account, without limitation, the planning needs of the Research Collaboration and the responsibilities of the JRC; provided, that, during the Research Collaboration Term, the JRC
shall meet at least every [***]. In addition, the JRC may meet on an ad hoc basis on not less than [***] notice (if the meeting is to be conducted in person) or [***] notice (if the meeting is conducted by teleconference). The Parties shall mutually
agree upon the times and places for such meetings, alternating between Watertown, Massachusetts and Tokyo, Japan, or such other location as members of the JRC shall agree. Each Party shall bear its own costs associated with holding and attending
such meetings. If mutually agreed by the Parties, such meetings may be held by videoconference or teleconference. An agenda shall be agreed upon by the JRC members and be distributed to the Parties by the hosting Party no less than [***] before any
meeting. If a representative of a Party on the JRC is unable to attend a meeting of the JRC, such Party may designate an alternate to attend such meeting and vote on behalf of such missing representative. In addition, each Party may, at its
discretion and upon written notice to the other Party, invite nonvoting employees, consultants or advisors (which consultants and advisors shall be under an obligation of  

  
 18 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
confidentiality no less stringent than those terms set forth herein) to attend any meeting of the JRC. Minutes shall be kept of all JRC meetings by the hosting Party and sent to all members of
the JRC for review and approval within [***] after each meeting. Minutes shall be deemed approved unless any member of the JRC objects to the accuracy of such minutes by providing written notice to the hosting Party within [***] of receipt of the
minutes; provided, that, in the event of any such objection by a Party that the Parties are unable to resolve, such minutes shall simply reflect such unresolved differences of opinion. 

2.4.3 Joint Research Committee Responsibilities. The JRC shall have the following responsibilities: 

(a) monitoring the progress of the Research Collaboration and of the conduct by the Parties of all research activities thereunder; 

(b) providing a forum for consensual discussion with respect to the Research Collaboration and of the conduct by the Parties of all research
activities thereunder with the goal of having one or more Research Compounds achieve the applicable Criteria; 
 (c) reviewing data,
reports or other information submitted by the Parties with respect to work conducted in the Research Collaboration; and 
 (d) discussing
such other matters as appropriate with respect to the Research Collaboration during the Research Collaboration Term. 
 2.4.4
Joint Research Committee Decisions. At each JRC meeting, (a) the presence in person of at least [***] shall constitute a quorum and (b) the representatives of a Party shall have one (1) collective vote on all
matters before the JRC at such meeting. All decisions of the JRC, shall be made by unanimous vote. If the JRC is unable to reach a unanimous vote on any matter, the matter shall be referred to the JSC for resolution pursuant to Section 2.3.4.

 2.5 Expiration of Research Collaboration Term. At the expiration of the Research Collaboration Term, the JRC shall be
disbanded and the Parties shall communicate directly with each other with respect to the activities contemplated by this Agreement in such manner as is reasonable and practical, including by having periodic telephonic and face-to-face meetings as
necessary. 
 2.6 Alliance Managers. Each Party shall have the right, but not the obligation, to appoint a person who shall
oversee interactions between the Parties for all matters related to the Research Collaboration and/or the development and commercialization of Research 

  
 19 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Compounds and Licensed Products (each, an “Alliance Manager”). The Alliance Managers shall have the right to attend all meetings of the JSC and JRC as non-voting
participants and may bring to the attention of the Parties any matters or issues either of them reasonably believes should be discussed and shall have such other responsibilities as the Parties may mutually agree in writing. Each Party may replace
its Alliance Manager at any time or may designate different Alliance Managers by notice in writing to the other Party.  
 2.7
Appointment Not an Obligation. The appointment of any members of a committee and any Alliance Manager is a right of each Party and not an obligation and shall not be a “deliverable” as defined in EITF Issue No. 00-21. Each
Party shall be free to determine not to appoint members of any committee and not to appoint an Alliance Manager. If a Party does not appoint members of a committee and/or an Alliance Manager, it shall not be a breach of this Agreement, nor shall any
consideration be required to be returned. 
 ARTICLE 3 

THE RESEARCH COLLABORATION 

3.1 Overview of Research Collaboration. DICERNA and KHK shall use Commercially Reasonable Efforts to conduct the Research
Collaboration, focused on the goals set forth in Section 2.2, in accordance with the Research Collaboration Plan or as otherwise agreed by the Parties.  

3.2 [***] DDS Technology. The Parties shall discuss whether or not to [***]. For purposes of clarity, the respective
rights of each Party in [***]. If the Parties are unable to agree whether or not to [***]. 
 3.3 Research Collaboration
Term. 
 3.3.1 Research Collaboration Term. The Research Collaboration for the Initial Target shall commence on
the Effective Date and continue, unless earlier terminated by the Parties, until [***] from the Effective Date unless extended by KHK and reasonably agreed by DICERNA (the “Research Collaboration
Term”); provided, that, if any [***] Target or [***] Target that is a Program Target is part of ongoing activities being conducted in the Research Collaboration as set forth in the applicable Research Collaboration
Plan which are not completed on or before the expiration of such [***] period, the Research Collaboration Term with respect to such [***] Target or [***] Target shall be extended, unless earlier terminated by the Parties, for a period to be
reasonably agreed by the Parties not to exceed [***] from the date of the applicable [***] Target Exercise Notice or the date of exercise of such [***] Right, as the case may be, but no later than the completion of the applicable research activities
or achievement of the applicable Lead Transfer Milestone.  

  
 20 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 3.3.2 Extended Research Term. The Research Collaboration for any [***]
Targets and any [***] Targets that are Program Targets shall commence on the date of payment by KHK of the applicable [***] set forth in Section 7.2.5 and, with respect to any [***] Target that replaces the Initial Target pursuant to
Section 4.1(a)(ii), as the date of such replacement and in each such case continue, unless earlier terminated by the Parties, for a period of [***], unless otherwise reasonably agreed by the Parties, but no later than the completion of such
research activities or achievement of the applicable Lead Transfer Milestone. 
 3.4 Research Collaboration Plans. The
Research Collaboration Plan for the Initial Target has been prepared by the Parties and attached hereto as Exhibit A. An update of such Research Collaboration Plan, and Research Collaboration Plans for each other Program Target, shall be
prepared by, or at the direction of, the Parties and submitted to the JSC for its approval. 
 3.5 Funding; Costs of
Manufacture. 
 3.5.1 Funding. During the Research Collaboration Term, KHK will provide research funding to DICERNA
for the discovery, characterization and testing of Research Compounds based on the Research Collaboration Plan prepared for the Initial Target. In consideration of the conduct by DICERNA of such research activities, KHK shall pay to DICERNA [***];
provided, that, in the event KHK terminates the Research Collaboration for the Initial Target, (i) KHK shall have no obligation to provide the research funding beyond such date of termination and (ii) DICERNA shall continue to have the
obligation to provide research for the discovery, characterization and testing of Research Compounds for any Program Targets other than the Initial Target in accordance with the applicable Research Collaboration Plan with no additional funding from
KHK, but except as otherwise agreed by the Parties, shall have no obligation beyond such activities and Program Targets. Notwithstanding the foregoing, if KHK replaces the Initial Target with an [***] Target as provided in Section 4.1(b)(ii),
KHK shall continue to pay DICERNA the research funding in accordance with this Section 3.5.1 with respect to such replacement Target but each payment of (a) (b) (c) shall not be paid more than one time in any event. 

3.5.2 Manufacturing Costs. 

(a) DICERNA, at its sole cost, shall manufacture or obtain DsiRNA-Based Compound for the conduct of the Research Collaboration for the
Initial Target 

  
 21 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
in the quantities described in the Research Collaboration Plan attached as Exhibit A; provided, that, such quantities shall not exceed the quantity of such DsiRNA-Based Compound specified
in Exhibit A. To the extent DICERNA’s cost to manufacture or obtain such materials exceeds $[***] USD ([***] dollars), DICERNA shall provide KHK with written notice, together with records which show such cost to manufacture or to obtain
the materials from a CMO (in such case an invoice from the CMO), and KHK shall pay DICERNA a transfer price for such materials manufactured or obtained by DICERNA on and after such date equal to [***]. 

(b) DICERNA shall manufacture or obtain all DsiRNA-Based Compound for the conduct of the Research Collaboration for each Program Target
(including, in the event Initial Target is replaced with an [***] Target, such [***] Target) other than Initial Target in the quantities mutually agreed by the Parties which shall be described in the Research Collaboration Plan for such Program
Target. To the extent DICERNA’s cost to manufacture or obtain such materials exceeds $[***] USD ([***] dollars), DICERNA shall provide KHK with written notice, together with records which show such cost to manufacture or to obtain the materials
from a CMO (in such case an invoice from the CMO), and KHK shall pay DICERNA a transfer price for such materials manufactured or obtained by DICERNA on and after such date equal to [***]. 

3.6 Conduct of Research Collaboration. 

3.6.1 Responsibilities of the Parties. During the Research Collaboration Term, each Party shall use Commercially
Reasonable Efforts to conduct the research activities for which it is responsible in accordance with the applicable Research Collaboration Plan. Without limiting the foregoing, (i) DICERNA shall be solely responsible for the identification,
preparation and characterization of Research Compounds meeting the In Vitro Criteria and In Vivo Criteria and (ii) the Parties shall both be responsible for optimizing Research Compounds until the
selection of an appropriate DDS Technology is determined and the appropriate DDS Technology performance for each Program Target is confirmed.  

3.6.2 Research Collaboration Staffing. KHK and DICERNA employees involved in the Research Collaboration will conduct the
research activities in a manner as required to maintain progress on the objectives of the Research Collaboration as set forth herein and in the Research Collaboration Plan. To achieve these objectives, KHK and DICERNA will assign qualified employees
to conduct such research activities. Each Party shall bear the travel, lodging and meal expenses of any of its employees who visit the other Party’s facilities in connection with the Research Collaboration and shall not be reimbursed by the
other Party for any such expenses. 

  
 22 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 3.6.3 Subcontracting. Either Party may subcontract to a Third Party any portion
of the activities assigned to it under the Research Collaboration Plan; provided, that, (a) KHK or DICERNA, as applicable, obtains a written agreement with such Third Party containing appropriate confidentiality and non-use provisions and
written assignments to KHK or DICERNA, as applicable, of all Patent Rights and Know-How that such subcontractors may develop by reason of work performed under such contract and (b) any Third Party subcontractor is required to perform its
services in accordance with any applicable generally accepted professional standards, including regulatory standards, as well as standards designated by the JRC or JSC (if any) and any Applicable Laws. 

3.6.4 Staff Availability. Each Party shall require its employees and permitted subcontractors engaged in the Research
Collaboration to be reasonably available upon reasonable notice during normal business hours at their respective places of employment to consult with the other Party on issues arising during Research Collaboration and in connection with any request
from any regulatory agency, including those relating to regulatory, scientific, and technical issues. 
 3.6.5 Facility
Visits. Representatives of KHK and DICERNA may, upon reasonable advance notice and during normal business hours, visit the facilities where the Research Collaboration work is being conducted. 

3.6.6 Exchange of Information. Subject to the terms of this Agreement and any confidentiality obligations to Third Parties, each
Party will promptly make available and disclose to the other Party such information regarding Research Compounds, Program Targets, DDS Technology and other information generated in carrying out the Research Collaboration as set forth in the Research
Collaboration Plan. All Program Technology conceived or reduced to practice in the course of the Research Collaboration by a Party will be promptly disclosed to the other Party. At a Party’s request, the other Party will provide written reports
of any studies performed by such other Party as part of the Research Collaboration required to support regulatory submissions relating to Licensed Products to be made by such requesting Party or its sublicensees without any compensation and will
allow such requesting Party and its sublicensees to use the data included in such reports to support such submissions. The Parties shall use reasonable efforts to communicate often by telephone, electronic mail or other mechanisms to keep each Party
fully advised of the activities being carried out by a Party under the Research Collaboration. 
 3.6.7 Reports. Without
limiting the generality of the foregoing, each Party shall, at least once each [***] during the Research Collaboration Term, provide reports to the JRC in reasonable detail regarding the status of its activities under the Research Collaboration and
such additional information that it has in its possession as may be reasonably requested from time to time by the JRC. 

  
 23 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 3.6.8 Records. KHK and DICERNA will each maintain records in sufficient
detail and in good scientific and business manner appropriate for purposes such as patent and regulatory matters, which records will be complete and accurate and will fully and properly reflect all work done and results achieved in the performance
of the Research Collaboration, including prompt signing and corroboration of laboratory notebooks and conception documents. 
 3.6.9
Compliance. All research activities conducted in connection with the Research Collaboration shall be carried out in compliance with any Applicable Laws governing the conduct of research at the site where such activities are being
conducted. Without limiting the foregoing, all animals involved in the Research Collaboration shall be provided humane care and treatment in accordance with generally acceptable current veterinary practices. 

3.7 [***] Technology Transfer. To the extent necessary for the conduct of the Research Collaboration by DICERNA, KHK
shall, at its sole cost and expense, provide such disclosure to DICERNA of the KHK [***] DDS Technology and such technical advice or assistance related thereto as KHK reasonably determines to be reasonably necessary. 

3.8 Independent DDS Technology. 

3.8.1 KHK Rights. In the event that KHK conducts research during the Term involving the application of any Independent DDS
Technology Controlled by it to any DsiRNA-Based Compound for any Program Target outside the Research Collaboration, it may select, at its sole discretion, such DsiRNA-Based Compound (combined with such Independent DDS Technology) as a Research
Compound by providing written notice to DICERNA. 
 3.8.2 DICERNA Rights. In the event that DICERNA conducts research during
the Term involving the use of any Independent DDS Technology Controlled by it to any DsiRNA-Based Compound for any Target, DICERNA may, at its sole discretion and at any time during the Research Collaboration Term, include any such Independent DDS
Technology as DICERNA Background DDS Technology at no additional consideration payable by KHK. Provided, however, in the event DICERNA conducts the research for any Program Target, whether or not DICERNA intends to include such Independent DDS
Technology into the DICERNA Background DDS Technology, DICERNA shall report to KHK the progress and result of such research from time to time and shall not disclose to any Third Party any information or data generated from such research without a
prior written consent of KHK. 

  
 24 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 3.9 Research Collaboration Exclusivity. During the Research
Collaboration Term, neither DICERNA nor KHK will develop or commercialize any siRNA compound for any Program Target for use in the Secondary Field in the Territory, whether internally developed by such Party or in-licensed from, or out-licensed to,
any Third Party, outside of this Agreement. 
 ARTICLE 4 

SELECTION OF PROGRAM TARGETS; OPTION RIGHTS 

4.1 Selection of Program Targets. 

(a) Initial Target. 

(i) The Parties hereby acknowledge and agree that the Initial Target has been designated by the Parties as a Program Target as of the
Effective Date for the Primary Field and is listed as such on the Program Target List attached hereto as Schedule 5-A. KHK shall have the right, at its sole discretion and at any time during the Research Collaboration Term, based on the
Development Criteria and the results of the Research Collaboration, to determine to proceed with further research and development of Research Compounds with respect to the Initial Target by providing written notice to DICERNA and paying the Initial
Target Option Payment (the “Initial Target Option Right”). [***] 
 (ii) If at any time after the date of payment
of the Upfront Payments and continuing for the remainder of the Research Collaboration Term for the Initial Target, KHK determines, after consultation with its internal patent counsel, that the DICERNA Background Patent Rights that cover the Initial
Target are reasonably likely to fail to provide KHK with the freedom to operate necessary for KHK to develop and commercialize DsRNAi-Based Compounds against such Initial Target, KHK shall provide DICERNA with a written notice of such decision, and
KHK shall have the one-time right to replace that Initial Target with one (1) [***] Target listed on the [***] Target List, at its sole discretion. Upon written notice by KHK to DICERNA of KHK’s decision to make such replacement,
(A) KRAS shall be deemed to be a Waived Target, and (B) the replacement [***] Target shall be deemed to be the Initial Target for purposes of this Agreement. For purposes of clarity, any Initial Target Option Payment or [***] previously
paid by KHK for the Initial Target that is replaced by an [***] Target under this Section 4.1(a)(ii) shall not be payable for such replaced Target; provided, that, all unpaid future milestones shall remain due and payable for such replaced
Target. 

  
 25 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (b) [***] Targets. 

(i) Exercise of Rights to [***] Targets. The Parties hereby acknowledge and agree that [***] Targets, as listed
on the [***] Target List attached hereto as Schedule 5-B, have been so designated by the Parties as of the Effective Date (each, an “[***] Target”). During the period commencing on the Effective Date and continuing for
a period of [***] (the “[***] Target Period”), KHK shall have the [***] (the “[***] Option”) to designate any [***] Target as a Program Target by providing written notice to DICERNA, which notice shall
identify the [***] Target (the “[***] Target Exercise Notice”). Upon receipt by DICERNA of an [***] Target Exercise Notice and payment of the applicable fees, the Parties shall promptly amend Schedule 5-A to include
such [***] Target as a Program Target and such [***] Target shall be a Program Target for purposes of this Agreement. [***] 
 (ii) [***].
[***] 
 (c) Additional Targets. 

(i) Additional Target Option Period. During the period commencing on the Effective Date and continuing for a period of [***] (the
“Additional Target Option Period”), KHK shall have the right to request that up to [***] additional Targets (the “Additional Targets”) be included in the Research Collaboration as [***]
Targets by providing written notice to DICERNA, which notice shall identify each such Additional Target (each, an “Additional Target Notice”). [***] 

(ii) [***]. [***] 
 (iii)
Limitation on Number of [***] Targets. Notwithstanding anything to the contrary in this Agreement, under no circumstances shall KHK have, at any one time, more than [***] Targets on the [***] Target List. 

4.2 Designation of Research Compounds. KHK shall have the sole right, in its sole discretion, by providing written notice
to DICERNA at any time on or before the expiration of the Research Collaboration Term, to (a) designate any DsiRNA-Based Compound as a Research Compound, and (b) determine in its sole discretion not to continue the development and
commercialization of any Research Compound against a Program Target. 

  
 26 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 4.3 Supply of Proprietary Materials. From time to time during the
Research Collaboration Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”) with Proprietary Materials of the Transferring Party
for use in the Research Collaboration. In connection therewith, each Recipient Party hereby agrees that (a) it shall not use such Proprietary Materials for any purpose other than exercising its rights or performing its obligations under this
Agreement; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws; (c) it shall not transfer any such Proprietary Materials to any Third Party without the prior written consent of the Transferring Party,
except as expressly permitted by this Agreement; (d) the Recipient Party shall not acquire any right, title or interest in or to such Proprietary Materials as a result of such supply by the Transferring Party; and (e) upon the expiration
or termination of the Research Collaboration Term, the Recipient Party shall, if and as instructed by the Transferring Party, either destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license
hereunder. 
 ARTICLE 5 

DEVELOPMENT, COMMERCIALIZATION, 

MANUFACTURING AND SUPPLY 

5.1 KHK Development Responsibility. Except for the conduct by DICERNA of Co-Promotion Activities with respect to Co-Promoted
Products pursuant to a Co-Promotion Agreement, on and after the date of exercise by KHK of the Initial Target Option Right, or the payment of any Lead Transfer Milestone for any [***] Target(s) or [***] Target(s), as the case may be, KHK shall be
solely responsible for (a) the conduct of all development, clinical development, manufacturing, regulatory and commercial activities related to Research Compounds and Licensed Products in the Field and in the Territory and (b) for the
conduct of all regulatory activities for the Licensed Products in the Territory, including making all regulatory filings applicable thereto and will own all Registrations applicable thereto in the Territory. 

5.2 Registrations. KHK (either directly or through any Affiliate or Sublicensee) shall have the right to apply for and shall own
all Registrations for Licensed Products in any country of the Territory that it chooses. KHK agrees to use Commercially Reasonable Efforts to obtain (either directly or through an Affiliate or Sublicensee) Registrations in each Major Market Country.
If KHK does not seek Registration in any country that is not a Major Market Country and DICERNA believes that such country has a sufficient potential market for the Licensed Product to be worthy of Registration, DICERNA shall provide KHK with
written notice and KHK shall be required to explain to DICERNA the reasons behind KHK’s decision not to seek Registration in such country. 

  
 27 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 5.3 Development and Commercialization Plans. KHK shall prepare, and submit to
DICERNA for its review, a development and commercialization plan for each Licensed Product to be developed and/or commercialized by KHK under this Agreement (each, a “Development and Commercialization Plan”)
within [***] after the designation by KHK of such Licensed Product and, in any event, prior to the initiation of development activities with respect to such Licensed Product. Thereafter, for each [***] during the Term, KHK shall provide DICERNA with
updates with respect to all significant development decisions made and actions taken by KHK with respect to such Development and Commercialization Plan. 

5.4 Manufacturing. KHK shall have the sole right and responsibility, at its sole cost and expense, for all aspects of the
manufacture and supply of the Licensed Products in the Territory; provided, that, (a) KHK shall keep DICERNA informed as to its manufacturing strategies and the progress made with respect thereto, and (b) if requested in writing by KHK,
DICERNA shall reasonably collaborate with KHK or its designated party, at KHK’s sole cost and expense, to the extent that technology transfer is required to manufacture the Licensed Products. KHK shall have the right to use CMOs and/or
analytical laboratories, at its sole discretion, to fulfill its responsibilities for the manufacture and supply of the Licensed Products in the Territory. 

5.5 Development and Commercialization Diligence. KHK shall exercise Commercially Reasonable Efforts to develop each Licensed
Product in the Field in the Territory, using the level of resources and effort which (a) are necessary to meet the timetable set forth in the Development and Commercialization Plan applicable to such Licensed Product and (b) are at a level
that is consistent with those which it would apply to a product of comparable potential resulting from its own programs. KHK will keep DICERNA reasonably informed concerning the status of its development and commercialization of each Licensed
Product. 
 5.6 Compliance. KHK shall perform its obligations under each Development and Commercialization Plan in good
scientific manner and in compliance with all Applicable Laws. 
 5.7 Reports; Information; Updates. 

(a) Development Reports. KHK shall keep DICERNA regularly informed of the progress of its efforts to develop Licensed Products in the
Field in the Territory. Without limiting the generality of the foregoing, KHK shall, at least once each [***], provide DICERNA with reports in reasonable detail regarding the status of all preclinical IND-enabling studies and activities (including
toxicology and pharmacokinetic studies), 

  
 28 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
clinical trials and other activities conducted and such additional information that they have in their possession as may be reasonably requested from time to time by DICERNA; provided, that, for
so long as DICERNA has in effect a Co-Promotion Option with respect to a Licensed Product, such reports shall include a summary of all Development Costs incurred by KHK over such [***]. 

(b) Commercialization Reports. KHK shall keep DICERNA regularly informed of the progress of KHK’s efforts to commercialize
Licensed Products in the Field in the Territory through periodic updates. Without limiting the generality of the foregoing, on and after the initiation by KHK of a Phase III Clinical Trial with respect to a Licensed Product, KHK shall provide
DICERNA with [***] written updates to each Development and Commercialization Plan, which shall identify the Drug Approval Applications with respect to such Licensed Product that KHK or any of its Affiliates or Sublicensees have filed, sought or
obtained in the prior [***] period or reasonably expect to make, seek or attempt to obtain in the following [***] period. In addition, KHK shall provide such additional information that it has in its possession as may be reasonably requested by
DICERNA regarding the commercialization of any Licensed Product, which request shall not be made more than once each [***]. 
 5.8
Adverse Event Reporting. In addition to the updates described in Section 5.7, KHK shall promptly provide DICERNA with (a) all Serious Adverse Event information relating to Licensed Products as such information is compiled or
prepared by KHK in connection with the development or commercialization of any Licensed Product and, (b) copies of Periodic Safety Update Reports (Volume 9E of the Rule Covering Medical Product in the EU). 

5.9 Co-Promotion Option. 

(a) Notice by KHK. KHK shall give DICERNA written notice of its intent to submit an NDA to the FDA with respect to each Licensed
Product for the Initial Target at least [***] prior to the anticipated date of such submission (each, an “NDA Submission Notice”), which NDA Submission Notice shall include a written report setting forth in reasonable detail
all Development Costs incurred by KHK with respect to such Licensed Product through the date of the NDA Submission Notice. Following its receipt of the NDA Submission Notice, DICERNA shall have the right, upon written notice, to review all Drug
Approval Applications prepared for such Licensed Product for the Initial Target, including the NDA, and all correspondence submitted or received with respect to such Licensed Product, at DICERNA’s sole cost and expense. 

  
 29 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (b) Exercise of Co-Promotion Option. DICERNA shall have the option (the
“Co-Promotion Option”), but not the obligation, to Co-Promote any Licensed Product for the Initial Target in the Co-Promotion Territory, by, at any time during the Co-Promotion Option Exercise Period applicable to that
Licensed Product (i) providing written notice to KHK (the “Co-Promotion Option Notice”), which notice shall specify the applicable Licensed Product and (ii) paying KHK the Co-Promotion Option Exercise Payment
applicable thereto. If DICERNA exercises a Co-Promotion Option with respect to a Licensed Product as described in this Section 5.9(b), such Licensed Product will thereafter be deemed to be a Co-Promoted Product for purposes of this Agreement
and the following provisions shall thereafter apply: 
 (i) the Parties shall promptly negotiate and execute a Co-Promotion Agreement for
such Co-Promoted Product in accordance with Section 5.9(c); 
 (ii) each Party shall share in the responsibility for the conduct of
Co-Promotion activities with respect to such Co-Promoted Product in the Co-Promotion Territory in accordance with the Co-Promotion Agreement; and 

(iii) KHK shall not pay to DICERNA any royalties for the Net Sales of such Licensed Product in the Co-Promotion Territory; provided, that,
DICERNA shall receive a 50:50 cost and profit sharing in lieu thereof, in accordance with the provisions as shall be set forth in the Co-Promotion Agreement. 

(c) Co-Promotion Agreement; Co-Promotion Plan. Within [***] of the date of exercise by DICERNA of a Co-Promotion Option, the Parties
shall (i) negotiate and execute a Co-Promotion Agreement (the “Co-Promotion Agreement”) which shall provide for the terms applicable to such Co-Promotion and (ii) prepare a marketing and sales plan (the
“Co-Promotion Plan”) for each Co-Promoted Product for the Co-Promotion Territory incorporating the terms set forth in the term sheet attached as Schedule 7, and with all other details and matters determined by mutual
good faith discussions and agreement of the Parties. In the event the Parties fail to execute and deliver the Co-Promotion Agreement within such [***], the Parties shall each produce a list of issues on which they have failed to reach agreement and
submit its list to be resolved in accordance with Section 13.5. 
 ARTICLE 6 

GRANT OF LICENSE RIGHTS 

6.1 License to KHK. DICERNA hereby grants to KHK and its Affiliates a royalty-bearing license to (a) DICERNA Background
Dicer Substrate Patent Rights, DICERNA Background Dicer Substrate Technology, DICERNA Program Patent Rights, 

  
 30 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
DICERNA Program Technology, DICERNA KRAS-Specific Patents and DICERNA’s interest in Joint Technology and Joint Patent Rights and (b) to DICERNA Background DDS Patent Rights and DICERNA
Background DDS Technology, solely to the extent such DICERNA Background DDS Patent Rights (the Patent Rights described in (a) and (b) above being referred to collectively as the “DICERNA Patent Rights”) and such
DICERNA Background DDS Technology (the Technology described in (a) and (b) above being referred to collectively as the “DICERNA Technology”) are selected by KHK for a Research Compound or Licensed Product, in any
case, to the extent necessary to research, develop, make, have made, use, offer for sale, sell and import Research Compounds and Licensed Products (i) in the Primary Field (with respect to Research Compounds and Licensed Products for the
Initial Target, subject to the payment of the applicable fee herein), (ii) in the Secondary Field (with respect to Research Compounds and Licensed Products for the Initial Target, subject to the payment by KHK of [***]) and (iii) subject
to the payment by KHK of all applicable payments required under this Agreement, including the payment of the applicable Lead Transfer Milestone, in the Secondary Field (with respect to Research Compounds and Licensed Products for any [***] Target
and [***] Target), in the Territory. Such licenses shall (a) be exclusive for the Initial Target in the Primary Field and in the Secondary Field, subject to the payment by KHK of [***] and exclusive for the [***] Targets and the [***] Targets
in the Secondary Field, other than Waived Targets; provided, that, DICERNA shall, and hereby does, reserve all rights under DICERNA Patent Rights and DICERNA Technology necessary for it to undertake research as part of the Research Collaboration and
to Co-Promote Co-Promoted Products, and (b) include the right for KHK and its Affiliates to grant sublicenses to Third Parties in accordance with Section 6.2. 

6.2 Right to Sublicense. KHK shall have the right to grant sublicenses to Sublicensees under the licenses granted to it
under Section 6.1 with respect to any Research Compounds and/or Licensed Products; provided, that, [***].  
 6.3 License
to DICERNA. KHK hereby grants to DICERNA a non-exclusive, royalty-free license to KHK Background Patent Rights and KHK Program Patent Rights and KHK’s interest in Joint Technology and Joint Patent Rights solely for the purpose of and to
the extent necessary for DICERNA to perform its obligations under this Agreement, including in order for DICERNA to undertake research as part of the Research Collaboration and to Co-Promote Co-Promoted Products; provided, that, the foregoing shall
not include a license to KHK [***] DDS Technology unless such KHK [***] DDS Technology is selected by KHK for a Research Compound. 

  
 31 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 6.4 License Exclusivity. Subject to Section 3.8, during the Term of this
Agreement, neither DICERNA nor KHK will, except as contemplated by this Agreement (a) develop or commercialize any Research Compound or Licensed Product, or any Program Target with respect to which such Research Compound or Licensed Product
interacts, for use in the Secondary Field in the Territory, whether internally developed, in-licensed or out-licensed or (b) develop or commercialize (or cause to be developed or commercialized) any pharmaceutical product with respect to any
Program Target using any DsiRNA-Based Compound (whether or not a Research Compound) for use in the Secondary Field in the Territory, whether internally developed, in-licensed or out-licensed; provided that, the foregoing restrictions shall not apply
to the development or commercialization by DICERNA of Waived Targets (and or Waived Compounds in respect thereof). 
 ARTICLE 7 

FINANCIAL PROVISIONS 

7.1 Upfront Payments. Within [***] of the Effective Date, KHK shall pay to DICERNA (a) a non-refundable,
non-creditable license fee in the amount of $[***] USD ([***] dollars) in consideration of the licenses granted under this Agreement for worldwide exclusive rights to the Initial Target in the Primary Field; and (b) a non-refundable,
non-creditable option fee in the amount of $[***] USD ([***] dollars) in consideration of the [***] Option for [***] [***] Targets (the “Upfront Payments”). Such Upfront Payments
shall be payable by KHK by wire transfer of immediately available funds in accordance with wire transfer instructions of DICERNA provided in writing to KHK prior to the Effective Date. 

7.2 Option Exercise Fees. 

7.2.1 Initial Target Option Right. Within [***] of the exercise by KHK of the Initial Target Option Right with respect to the
Initial Target, KHK shall pay to DICERNA [***] (the “Initial Target Option Payment”). 
 7.2.2 [***]. [***]. 

7.2.3 [***] Target Right. For each [***] Target, within [***] of the exercise by KHK of each [***] Option, KHK shall pay to
DICERNA a non-refundable, non-creditable payment of $[***] USD ([***] dollars) per [***] Target (the [***] Target Payment”). 

7.2.4 Satisfaction of [***] Target Criteria. For each [***] Target of which [***] Option is exercised, KHK shall
pay to DICERNA a non-refundable, non-creditable confirmation fee in the amount of $[***]USD ([***] dollars) per [***] Target within [***] of the date that KHK confirms to KHK’s reasonable satisfaction that the [***] Target meets the In
Vivo Criteria applicable to such [***] Target as set forth in the Research Collaboration Plan (the [***] Target Criteria Satisfaction Payment”). 

7.2.5 [***] Targets. For each [***] Target, within [***] of such [***] Target for designation as a Program Target, KHK shall pay
to DICERNA a non-refundable, non-creditable [***] payment in the amount of $[***] USD ([***] dollars) per [***] Target (the “[***]”). 

  
 32 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 7.3 Lead Transfer Milestone. Within [***] of the confirmation by KHK that the
Research Compound(s) prepared and transferred by DICERNA and selected by KHK meets the Development Criteria for performance of DDS for each [***] Target [***] and [***] Target [***], KHK shall pay to DICERNA a non-refundable, non-creditable payment
in the amount of [***] (“Lead Transfer Milestone”) [***] Target [***] and [***] Target [***]. Regardless of how many different kinds of Licensed Products are developed or commercialized incorporating a
particular [***] Target [***] and [***] Target [***], only one of each Lead Transfer Milestone shall be payable with respect to such [***] Target [***] and [***] Target [***]. [***]. 

7.4 R&D Milestone Payments. 

7.4.1 Milestone Payments. KHK shall pay to DICERNA the following non-refundable, non-creditable cash milestone payments within
[***] of the occurrence of the following events with respect to each Licensed Product for any Program Target: 
  

					
	 Milestone Event (US$ Million)
	  	Amount (US$)	 
		
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 [***]
	  	$	[***	] 
	 TOTAL
	  	$	[***	] 

 7.4.2 Single Milestone Payment. For purposes of clarity, KHK shall make a milestone payment
corresponding to each of the foregoing milestone events only once per Licensed Product under Section 7.4.1, regardless of the number of times such milestone event occurs for such Licensed Product. 

  
 33 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 7.4.3 Abandoned Licensed Products. In the event that after one or more
milestone payments have been paid with respect to a Licensed Product for a Program Target, KHK abandons development efforts with respect to such Licensed Product and later performs development efforts in respect of the same Program Target using
different Research Compound(s) or by using a new combination of Research Compounds, then any milestone payments already paid for the abandoned Licensed Product in respect of such Program Target need not be paid again when the same milestone is
reached for the Research Compound or Research Compounds developed for the same Program Target. 
 7.4.4 Skipped Milestone
Events. A milestone payment shall be payable for any milestone event which is skipped to reach a subsequent milestone. For example, [***]. 

7.5 Commercial Milestone Payments. KHK shall pay to DICERNA the following non-refundable, non-creditable milestone
payments within [***] from the occurrence of the following events with respect to Licensed Products for any Program Target; provided, that, if DICERNA exercises a Co-Promotion Option with respect to a Co-Promoted Product, the Net Sales attributable
to the Co-Promoted Product in the Co-Promotion Territory shall not be counted for purposes of determining Annual Net Sales for the following milestone events for such Co-Promoted Product:  

 

					
	 Milestone Event
	  	Amount (US$)	 
		
	 [***]
	  	US$	[***	] 
	 [***]
	  	US$	[***	] 
	 [***]
	  	US$	[***	] 
	 TOTAL
	  	US$	[***	] 

 7.6 Royalty Payments. KHK shall pay to DICERNA a tiered royalty on incremental Annual Net Sales
of Licensed Products in the Royalty-Bearing Territory on a Licensed Product-by-Licensed Product and country-by-country basis commencing on the date of First Commercial Sale and continuing until the later to occur of (a) the last to expire of
any Patent Rights licensed hereunder applicable to the manufacture, use or sale of such Licensed Product, or (b) [***] years from the date of First Commercial Sale of such Licensed Product in such country (the “Royalty
Term”). Thereafter, with respect to such Licensed Product in such country, the licenses granted hereunder shall be an irrevocable, paid-up, royalty-free license. In the event DICERNA exercises the Co-Promotion Option for a Licensed
Product, KHK shall 

  
 34 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
not pay to DICERNA any royalties for the Net Sales of such Licensed Product in the Co-Promotion Territory; provided, that, DICERNA shall receive a 50:50 cost and profit sharing in lieu thereof,
in accordance with the provisions as shall be set forth in the Co-Promotion Agreement. 
  

					
	 Royalty Tier
	  	Royalty Rate	 
		
	 [***]
	  	 	[***]% ([***] percent	) 
	 [***]
	  	 	[***]% ([***] percent	) 
	 [***]
	  	 	[***]% ([***] percent	) 

 7.7 Royalty Offsets. 

7.7.1 No Valid Claim. If any Licensed Product is sold in a country in the Royalty-Bearing Territory and is not covered or
becomes not covered by a Valid Claim of the DICERNA Patent Rights, KHK Program Patent Rights or Joint Patent Rights in such country, the royalty rates in such country shall be reduced by [***] percent ([***]%) of the rates set forth in
Section 7.6 above; provided, that, in the event the royalty rate on a Licensed Product is reduced in a country under this Section 7.7.1 and is subsequently covered by a Valid Claim under the DICERNA Patent Rights, KHK Program Patent Rights
or Joint Patent Rights in such country, the full royalty rates otherwise applicable under Section 7.6 shall be reinstated for the remainder of the applicable Royalty Term. The Parties hereby acknowledge and agree that any royalties that are
payable for a Licensed Product for which no Valid Claim of Patent Rights exist shall be in consideration of (a) the performance by DICERNA of the Research Collaboration; (b) DICERNA’s expertise and know-how concerning the
identification of Research Compounds in the Field, including its development of the Dicer-Substrate Technology and its other DsiRNA-related activities conducted prior to the Effective Date; (c) the licenses granted to KHK hereunder with respect
to DICERNA Technology and Joint Technology that are not within the claims of any Patent Rights Controlled by DICERNA; (d) the exclusivity restrictions on DICERNA in this Agreement; and (e) the “head start” afforded to KHK by each
of the foregoing. 
 7.7.2 Generic Products. In the event that any Third Party that is not a Sublicensee of KHK sells a
Generic product for use in the Field in any country in the Territory in which a Licensed Product is then being sold by KHK then, during any Calendar Quarter in which sales of the Generic product by such Third Parties are equal to or greater than
[***] in such country for the preceding Calendar Quarter, the applicable royalties in effect with respect 

  
 35 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
to such Licensed Product in such country as specified in Section 7.6 above for each Calendar Quarter thereafter shall be reduced by [***] percent ([***]%). In the event that sales of the
Generic product by such Third Parties are equal to or greater than [***] in such country, the applicable royalties in effect with respect to such Licensed Product in such country shall be reduced to an amount equal to [***] percent ([***]%) of the
full royalty rates specified in Section 7.6 above (that is, [***] percent ([***]%) reduction). Notwithstanding the foregoing, (a) KHK’s obligation to pay royalties at the full royalty rates shall be reinstated on the first day of the
Calendar Quarter immediately following the Calendar Quarter in which sales of such Generic Product account for less than [***] in such country and (b) KHK’s obligation to pay royalties at [***] percent ([***]%) of the rates set forth in
Section 7.6 shall be reinstated on the first day of the Calendar Quarter immediately following the Calendar Quarter in which sales of such Generic Product account for more than [***] but less than [***] in such country. 

7.7.3 Combination of No Valid Claim and Generic Products. During such time when a Licensed Product is subject to [***] percent
([***]%) reduction in royalties in a given country pursuant to Section 7.7.1 due to the lack of a Valid Claim in such country, if the same Licensed Product is also subject to [***] percent ([***]%) reduction in royalties pursuant to
Section 7.7.2 due to competition from Generic products in such country, the royalties payable in such country shall in such case be reduced by [***] percent ([***]%) of the full royalty rates otherwise payable under Section 7.6, such that
the amount payable shall be equal to [***] percent ([***]%) of the full royalty rates otherwise payable under Section 7.6. 
 7.7.4
Third Party Payments. The amount of royalties payable to DICERNA under Section 7.6 for any Licensed Product in any country in the Royalty-Bearing Territory shall be reduced by [***] percent ([***]%) of the amount of any royalties
paid by KHK to any Third Party in consideration for the license of Patent Rights in such country if such Patent Rights would be infringed by the inclusion of the Research Compound in the Licensed Product in such country, as evidenced, to the extent
requested by DICERNA, by the written opinion of a neutral patent expert (patent counsel who (and whose firm) is not at the time of the opinion, and was not at any time during the [***] prior to such opinion, performing services for either of the
Parties) reasonably acceptable to DICERNA; provided, that, (a) KHK shall consult with DICERNA prior to entering into any agreement that provides for the payment of such royalties and (b) in no event shall the royalties payable with respect
to a Licensed Product in a country be reduced by more than [***] percent ([***]%) of what would otherwise be due with respect to such Licensed Product. 

7.7.5 Maximum Adjustment of Royalties. Notwithstanding anything to the contrary in this Agreement, under no circumstances shall
the cumulative application of the 

  
 36 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
adjustments described in Sections 7.7.1, 7.7.2, 7.7.3, 7.7.4, and 10.7.3 cause the royalty rates in Section 7.6 to be reduced in any Calendar Year below [***] percent ([***]%) of the rates
set forth in Section 7.6. 
 7.7.6 DICERNA Obligations. For purposes of clarity, DICERNA shall be solely responsible for
the amount of any royalties which DICERNA may be required to pay to any Third Parties for DICERNA Background Dicer Substrate Technology and DICERNA Background DDS Technology Controlled by DICERNA as of the Effective Date pursuant to agreements to
which DICERNA is a party and that are in effect as of the Effective Date. 
 7.8 Accounting Reports; Payment of
Royalty. KHK shall keep complete and accurate books and records necessary for DICERNA to ascertain and to verify all payments owed by KHK hereunder. KHK will make royalty payments to DICERNA for Licensed Products sold by KHK, its Affiliates
and Sublicensees during [***]. Each royalty payment will be accompanied by a written report for that [***] showing (a) the Net Sales of the Licensed Products sold by KHK, its Affiliates and Sublicensees during the [***] and the calculation of
the royalties payable under this Agreement; (b) the basis for any deductions from gross amounts billed or invoiced to determine Net Sales; (c) the applicable royalty rates for such Licensed Product; (d) the exchange rates used in
calculating any of the foregoing; and (e) a calculation of the amount of royalty due to DICERNA. 
 7.9 Audit
Rights. Upon the written request of DICERNA, and not more than once in each Calendar Year, KHK will permit DICERNA’s independent certified public accountant to have access during normal business hours to such of the records of KHK as
may be reasonably necessary to verify the accuracy of the royalty reports hereunder for the current year and the preceding [***] prior to the date of such request. The independent certified public accountant shall keep confidential any information
obtained during such inspection and shall report to DICERNA only the amounts of Net Sales and royalties due and payable. Upon the expiration of [***] following the end of any Calendar Year, the calculation of royalties payable with respect to such
year will be binding and conclusive upon DICERNA, and KHK and its Affiliates and Sublicensees will be released from any liability or accountability with respect to royalties for such Calendar Year. If such accounting firm concludes that additional
royalties were owed, or that KHK overpaid royalties, during such period, KHK will pay the additional royalties, or DICERNA shall return any overpaid royalties, within [***] of the date DICERNA delivers to KHK such accounting firm’s written
report. The fees charged by such accounting firm will be paid by DICERNA unless the additional royalties owed by KHK exceed [***] percent ([***]%) of the royalties paid for the royalty period subject to the audit, in which case KHK will pay the
reasonable fees of the accounting firm. KHK will include in each sublicense 

  
 37 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
granted by it pursuant to this Agreement a provision requiring the Sublicensee to make reports to KHK, to keep and maintain records of sales made pursuant to such sublicense and to grant access
to such records by a mutually-agreed upon independent accountant to the same extent required of KHK under this Agreement. DICERNA will treat all financial information subject to review under this Section 7.9 or under any sublicense agreement in
accordance with the confidentiality provisions of this Agreement, and will use reasonable effort to cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with KHK obligating it to retain all such financial
information in confidence pursuant to such confidentiality agreement. 
 7.10 Payments. All payments to a Party under
this Agreement will be made in United States Dollars by bank wire transfer of same day funds to such bank account as designated in writing by the other Party from time to time. Each Party will pay a late payment service charge of [***]% per [***]
(or the highest amount allowed by law, if lower than [***]% per [***]) on all past-due amounts owed by such Party under this Agreement. 

7.11 Income Tax Withholding. Each Party will be responsible for its own tax liabilities resulting from the payments
received from the other Party under this Agreement. If laws, rules or regulations require withholding of income taxes or other taxes imposed upon payments set forth in this Article 7, the paying Party will make such withholding payments to the
governmental authorities as required and subtract such withholding payments from the payments set forth in this Article 7. The paying Party will submit appropriate proof of payment of the withholding taxes to the other Party within a reasonable
period of time. The Parties will cooperate reasonably in completing and filing documents required under the provisions of any applicable tax laws or under any other Applicable Laws, in connection with the making of any required tax payment or
withholding payment, or in connection with any claim to a refund of or credit for any such payment. The Parties will cooperate to minimize such withholding taxes in accordance with Applicable Laws. 

7.12 Foreign Currency Exchange. If, in any Calendar Quarter, Net Sales are made in any currency other than United States
Dollars, such Net Sales shall be converted into United States Dollars as follows: 
 (A/B), where 

A = foreign “Net Sales” (as defined above) in such Calendar Quarter expressed in such foreign currency; and 

B = foreign exchange conversion rate, expressed in local currency of the foreign country per United States Dollar (using, as the applicable
foreign exchange rate, [***]. 

  
 38 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 ARTICLE 8 

CONFIDENTIALITY 
 8.1
Nondisclosure and Nonuse Obligations. All Confidential Information disclosed by a Disclosing Party to a Receiving Party hereunder will be maintained in confidence and will not be disclosed to any Third Party or used by the Receiving
Party for any purpose except as expressly permitted herein without the prior written consent of the Disclosing Party. Notwithstanding the foregoing, (a) either Party may disclose data generated during the Research Collaboration to such
Party’s employees who are subject to obligations of confidentiality and non-use with respect to such data no less restrictive than the obligations of confidentiality and non-use of the Receiving Party pursuant to this Article 8 and (b) the
Parties shall generally have free use of data generated and shared during the Research Collaboration for purposes relating to the development and commercialization of the Licensed Product and other activities related to their obligations arising
under this Agreement. For purposes of clarity, neither Party may use the Confidential Information of the other Party for internal research or development purposes other than for activities directly related to their obligations arising under this
Agreement. 
 8.2 Permitted Disclosure of Confidential Information. 

8.2.1 Permitted Disclosures. Notwithstanding Section 8.1, a Receiving Party may disclose Confidential Information of the
Disclosing Party: 
 (a) to appropriate U.S. and/or foreign tax authorities, to appropriate patent agencies in order to obtain and
prosecute Patent Rights pursuant to this Agreement, to appropriate Regulatory Authorities to gain approval to conduct clinical trials, obtain Registrations or to market Licensed Products pursuant to this Agreement; provided, that, any such
disclosure may be only to the extent reasonably necessary to obtain such Patent Rights or authorizations; 
 (b) if required by any
governmental authority other than under Section 8.2.1; provided, that, prior to such disclosure, the Party subject to the request for such disclosure (the “Notifying Party”) promptly notifies the other
Party of such requirement so that such other Party may seek a protective order or other appropriate remedy; and provided, further, that, in the event that no such protective order or other remedy is obtained, or that such other Party waives
compliance with this Article 8, the Notifying Party will furnish only that portion of the other Party’s Confidential Information that it is advised by counsel it is legally required to furnish and will exercise all reasonable efforts to
obtain reasonable assurance that confidential treatment will be accorded the other Party’s Confidential Information so furnished; 

  
 39 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (c) by a Party to its permitted sublicensees, agents, consultants, Affiliates and/or other
Third Parties for the research and development, manufacturing and/or marketing of Licensed Products (or for such Parties to determine their interest in performing such activities) in accordance with this Agreement on the condition that such
Affiliates and Third Parties agree to be bound by the confidentiality and non-use obligations contained in this Agreement; or 
 (d) if
required to be disclosed by law or court order; provided, that, notice is promptly delivered to the non-disclosing Party in order to provide an opportunity to challenge or limit the disclosure obligations. 

8.2.2 Additional Permitted Disclosures. In addition to the disclosures permitted under Section 8.2.1 above, DICERNA and KHK
each agrees that the Receiving Party may disclose the Confidential Information of the Disclosing Party (including the terms of this Agreement) (a) on a need-to-know basis to such Disclosing Party’s legal and financial advisors; (b) as
reasonably necessary in connection with an actual or potential (i) permitted sublicense of such Receiving Party’s rights hereunder, (ii) Third Party collaborators or licensees, or debt or equity financing of such Receiving Party,
subject in each case to written obligations of confidentiality substantially similar to those of the Parties hereunder, or (iii) merger or sale of all or substantially all of the Receiving Party’s business unit to which this Agreement
relates or in the event of the merger or consolidation or similar change of control involving such Receiving Party; (c) to any Third Party that is or may be engaged by the Receiving Party to perform services in connection with the Research
Collaboration; and (d) for any other purpose with the Disclosing Party’s written consent, not to be unreasonably withheld, conditioned or delayed. 

ARTICLE 9 
 DISCLAIMERS,
REPRESENTATIONS, WARRANTIES AND 
 INDEMNIFICATIONS 

9.1 KHK Representations and Warranties. KHK represents and warrants to DICERNA as follows: 

9.1.1 Corporate Existence and Authority. As of the Effective Date, KHK: (a) is a corporation duly organized, validly
existing and in good standing under the laws of Japan, (b) has full corporate power and authority and the legal right to own and operate its 

  
 40 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the options to license and licenses granted
hereunder, (c) has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, (d) has taken all necessary corporate action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder, and (e) has delivered this Agreement that has been duly executed and this Agreement constitutes a legal, valid, binding obligation of KHK and is enforceable against it
in accordance with its terms. 
 9.1.2 Patents. As of the Effective Date and to the best of KHK’s Knowledge, it
has the sufficient legal and/or beneficial title and ownership under the KHK Technology as is necessary to fulfill its obligations under this Agreement and to grant the licenses to DICERNA pursuant to this Agreement. KHK is not aware of any
communications alleging that it has violated or, by conducting its business as currently proposed under this Agreement, would violate any of the intellectual property rights of any Third Party. 

9.1.3 Absence of Litigation, Infringement, Misappropriation. As of the Effective Date and to the best of KHK’s Knowledge,
there is no pending or threatened litigation (and KHK has not received any communication relating thereto) which alleges that KHK’s activities under this Agreement would infringe or misappropriate any intellectual property rights of any Third
Party. To the best of KHK’s Knowledge, there is no material unauthorized use, infringement or misappropriation of any of its intellectual property rights that are the subject of the licenses or options to license granted hereunder. 

9.1.4 Full Disclosures. KHK has provided DICERNA with all information that DICERNA has requested for deciding the merits of
entering into this Agreement. 
 9.1.5 Employee Obligations. All KHK employees who will conduct research under this Agreement
have legal obligations requiring assignment to KHK of all inventions made in the course of and as a result of their association with KHK and obligating the individual to maintain as confidential the Confidential Information of KHK, as well as the
Confidential Information of DICERNA which KHK may receive. 
 9.1.6 Compliance with Laws. In carrying out its work under this
Agreement, all KHK work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is being conducted. Moreover,
KHK will carry out all work under the Research Collaboration in accordance with current Good Laboratory Practices, Good Clinical Practices, and Good Manufacturing Practices, if applicable, based on the specific work to be conducted. 

  
 41 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 9.1.7 No Debarment. Neither KHK nor any of its Affiliates has been debarred or
is subject to debarment. During the Term, KHK and its Affiliates will use Commercially Reasonable Efforts to avoid using in any capacity, in connection with the development, manufacture or commercialization of any Research Compound or Licensed
Product, any person who, to KHK’s Knowledge has been debarred pursuant to Section 306 (or comparable law or regulation) of the FDCA, or who to KHK’s Knowledge is the subject of a conviction described in such section. KHK agrees to
inform DICERNA in writing immediately if it or any person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 (or comparable law or regulation), or if any action, suit, claim,
investigation or legal or administrative proceeding is pending or, to the best of KHK’s Knowledge, is threatened, relating to the debarment or conviction of KHK or any person used in any capacity by KHK or any of its Affiliates in connection
with the development, manufacture or commercialization of any Research Compound or Licensed Product. 
 9.2 DICERNA Representations
and Warranties. DICERNA represents and warrants to KHK as follows: 
 9.2.1 Corporate Existence and Authority. As of
the Effective Date, DICERNA: (a) is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated, (b) has full corporate power and authority and the legal right to own and
operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the options to license and licenses granted hereunder, (c) has the corporate power and
authority and the legal right to enter into this Agreement and perform its obligations hereunder, (d) has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of
its obligations hereunder, and (e) has delivered this Agreement that has been duly executed and this Agreement constitutes a legal, valid, binding obligation of DICERNA and is enforceable against it in accordance with its terms; 

9.2.2 Patents. As of the Effective Date and to the best of DICERNA’s Knowledge, it has the sufficient legal and/or
beneficial title and ownership under the DICERNA Technology as is necessary to fulfill its obligations under this Agreement and to grant the licenses and options to license to KHK pursuant to this Agreement. DICERNA has no Knowledge of any
communications alleging that it has violated or, by conducting its business as currently proposed under this Agreement, would violate any of the intellectual property rights of any Third Party. 

  
 42 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 9.2.3 Absence of Litigation, Infringement, Misappropriation. As of the
Effective Date and to the best of DICERNA’s Knowledge, there is no pending or threatened litigation (and DICERNA has not received any communication relating thereto) which alleges that DICERNA’s activities under this Agreement would
infringe or misappropriate any intellectual property rights of any Third Party. To the best of DICERNA’s Knowledge, there is no material unauthorized use, infringement or misappropriation by any Third Party of any of DICERNA’s intellectual
property rights that are the subject of the licenses or options to license granted to KHK hereunder. 
 9.2.4 Full
Disclosures. DICERNA has provided KHK with all information that KHK has requested for deciding the merits of entering into this Agreement. 

9.2.5 Employee Obligations. All DICERNA personnel who will conduct research under this Agreement have legal obligations
requiring assignment to DICERNA of all inventions made in the course of and as a result of their association with DICERNA and obligating the individual to maintain as confidential the Confidential Information of DICERNA, as well as the Confidential
Information of KHK which DICERNA may receive; 
 9.2.6 Compliance with Laws. In carrying out its work under this Agreement,
all DICERNA work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is being conducted. Moreover,
DICERNA will carry out all work under the Research Collaboration in accordance with current Good Laboratory Practices, Good Clinical Practices, Good Manufacturing Practices, if applicable based on the specific work to be conducted. 

9.2.7 Licenses. DICERNA has not taken not will it take any action which would, in DICERNA’s good faith judgment, interfere
with any obligations of DICERNA set forth in this Agreement, including but not limited to the obligation to grant KHK the licenses and options to license hereunder. 

9.2.8 No Debarment. Neither DICERNA nor any of its Affiliates has been debarred or is subject to debarment. During the Term,
DICERNA and its Affiliates will use Commercially Reasonable Efforts to avoid using in any capacity, in connection with the development, manufacture or commercialization of any Research Compound or Licensed Product, any person who, to DICERNA’s
Knowledge has been debarred pursuant to Section 306 

  
 43 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
(or comparable law or regulation) of the FDCA, or who to DICERNA’s Knowledge is the subject of a conviction described in such section. DICERNA agrees to inform KHK in writing immediately if
it or any person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 (or comparable law or regulation), or if any action, suit, claim, investigation or legal or administrative proceeding
is pending or, to the best of DICERNA’s Knowledge, is threatened, relating to the debarment or conviction of DICERNA or any person used in any capacity by DICERNA or any of its Affiliates in connection with the development, manufacture or
commercialization of any Research Compound or Licensed Product. 
 9.3 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Without
limiting the generality of the foregoing, each Party expressly does not warrant (a) the success of any research undertaken in the course of the Research Collaboration or (b) the safety for any purpose of the technology it provides
hereunder. 
 9.4 Responsibility and Control. DICERNA and KHK shall each be solely responsible for the safety of
their respective employees, agents, licensees or sublicensees with respect to efforts employed under this Agreement and each shall hold the other harmless with regard to any liability for damages or personal injuries resulting from acts of its
respective employees, agents, licensees or sublicensees. 
 9.5 KHK’s Right to Indemnification. DICERNA
shall indemnify each of KHK, its Affiliates, Sublicensees, permitted successors and assigns, and the directors, officers, employees, agents and counsel thereof (the “KHK Indemnitees”), and defend and hold each KHK Indemnitee
harmless from and against any and all liabilities, damages, losses, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation reasonable attorneys’ fees) (any of the foregoing,
“Damages”) incurred by or asserted against any KHK Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, or violation of government
regulation but only to the extent arising from or occurring as a result of a claim or demand made by a Third Party (a “Third Party Claim”) against any KHK Indemnitee arising because of: (a) the breach of any
representation or warranty made by DICERNA pursuant to this Article 9; (b) any material breach of this Agreement by DICERNA; (c) the manufacture, use, handling, storage, sale or other disposition of a Co-Promoted Product that is sold
by 

  
 44 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
DICERNA, its Affiliates, agents or sublicensees; or (d) the gross negligence or willful misconduct of DICERNA except, in each such case in subparagraphs (a) through (d) above, for
any Damages for which KHK or any of its Affiliates has an obligation to indemnify DICERNA Indemnitees pursuant to Section 9.6, as to which Third Party Claim or Damages each Party will indemnify the other to the extent of their respective
liability for such Damages. 
 9.6 DICERNA’s Right to Indemnification. KHK shall indemnify each of DICERNA, its
Affiliates, sublicensees, successors and assigns, and the directors, officers, employees, agents and counsel thereof (the “DICERNA Indemnitees”), and defend and hold each DICERNA Indemnitee harmless from and
against any and all Damages incurred by or asserted against any DICERNA Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government
regulation but only to the extent arising from or occurring as a result of a Third Party Claim against any DICERNA Indemnitee arising because of: (a) the breach of any representation or warranty made by KHK pursuant to this Article 9;
(b) any material breach of this Agreement by KHK; (c) the development, manufacture, use, handling, storage, sale or other disposition of any Licensed Product that is sold by KHK, its Affiliates, agents or Sublicensees; or (d) the
gross negligence or willful misconduct of KHK except, in each such case in subparagraphs (a) through (d) above, for any Damages for which DICERNA or any of its Affiliates has an obligation to indemnify KHK Indemnitees pursuant to
Section 9.5, as to which Third Party Claim or Damages each Party will indemnify the other to the extent of their respective liability for such Damages. 

9.7 Indemnification Procedures. Promptly after a Party entitled to indemnification under Section 9.5 or 9.6 (an
“Indemnitee”) receives notice of any pending or threatened claim against it (an “Action”), such Indemnitee shall give written notice to the Party to whom the Indemnitee is entitled to look for
indemnification pursuant to Section 9.5 or 9.6, as applicable (the “Indemnifying Party”), of the commencement thereof; provided, that, the failure so to notify the Indemnifying Party shall not relieve it of any liability
that it may have to any Indemnitee hereunder, except to the extent the Indemnifying Party demonstrates that it is prejudiced thereby. In case any Action that is subject to indemnification under this Article 9, shall be brought against an
Indemnitee and it shall give written notice to the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate therein and, if it so desires, to assume the defense thereof with counsel reasonably
satisfactory to such Indemnitee and, after notice from the Indemnifying Party to the Indemnitee of its election to assume the defense thereof, the Indemnifying Party shall not be liable to such Indemnitee under this Article 9 for any fees of
other counsel or any other expenses, in each case subsequently incurred by such Indemnitee in connection with the defense thereof, other 

  
 45 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
than reasonable costs of investigation. Notwithstanding an Indemnifying Party’s election to assume the defense of any such Action that is subject to indemnification under this
Article 9, the Indemnitee shall have the right to employ separate counsel and to participate in the defense of such Action, and the Indemnifying Party shall bear the reasonable fees, costs and expenses of such separate counsel if: (a) the
use of counsel chosen by the Indemnifying Party to represent the Indemnitee would present such counsel with a conflict of interest; (b) the actual or potential defendants in, or targets of, any such Action include both the Indemnifying Party
and the Indemnitee, and the Indemnitee shall have reasonably concluded that there may be legal defenses available to it which are different from or additional to those available to the Indemnifying Party (in which case the Indemnifying Party shall
not have the right to assume the defense of such Action on the Indemnitee’s behalf); (c) the Indemnifying Party shall not have employed counsel satisfactory to the Indemnitee to represent the Indemnitee within a reasonable time after
notice of the institution of such Action; or (d) the Indemnifying Party shall authorize the Indemnitee to employ separate counsel at the Indemnifying Party’s expense. If an Indemnifying Party assumes the defense of such Action, no
compromise or settlement thereof may be effected by the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or delayed, unless (1) there is no finding or admission of any violation
of law or any violation of the rights of any other Party and no effect on any other claims that may be made against the Indemnitee and (2) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party. 

9.8 Insurance. Not later than [***] before the date on which KHK or any Affiliate or Sublicensee of KHK shall, on a commercial
basis, make, use, or sell any Licensed Products, KHK will, at its expense, obtain and maintain in full force and effect product liability insurance with a minimum coverage of $[***] per occurrence and $[***] annual aggregate. Upon request of
DICERNA, such insurance shall name DICERNA as an additional insured and shall provide for at least [***] notice to DICERNA of any cancellation or termination; provided, that, DICERNA shall reimburse KHK for any additional insurance fee incurred by
KHK for inclusion of DICERNA as an additional insured. 
 ARTICLE 10 

INTELLECTUAL PROPERTY 

10.1 Disclosures and Reports. During the Term, each Party shall promptly disclose to the other in writing all Program
Technology generated by such Party, which disclosure shall be in sufficient detail to permit the other Party to employ such Program Technology as provided herein. Within [***] of the termination or expiration of this Agreement, each Party shall
provide the other Party with a comprehensive final written report with respect to the Program Technology generated by such Party under this Agreement. 

  
 46 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 10.2 DICERNA Program Technology. DICERNA shall solely own all DICERNA Program
Technology and have the sole right to exploit such DICERNA Program Technology. KHK shall assign to DICERNA all of its rights to any such DICERNA Program Technology in which it has inventorship, and DICERNA shall and hereby does grant to KHK a
royalty-free, fully paid license to use such DICERNA Program Technology solely to the extent necessary for KHK to perform its obligations under this Agreement. 

10.3 KHK Program Technology. KHK shall solely own all KHK Program Technology and have the sole right to exploit such KHK Program
Technology. DICERNA shall assign to KHK all of its rights to any such KHK Program Technology in which it has inventorship, and KHK shall and hereby does grant to DICERNA a royalty-free, fully paid license to use any such KHK Program Technology
solely to the extent necessary for DICERNA to perform its obligations under this Agreement. 
 10.4 Joint Technology and Joint Patent
Rights. DICERNA and KHK shall jointly own all Joint Technology and Joint Patent Rights. Notwithstanding anything to the contrary contained herein or under Applicable Laws, subject to the licenses granted by each Party to the other Party
pursuant to this Agreement and except to the extent set forth in Article 8, the Parties hereby agree that any information and data contained in the Joint Technology shall be kept confidential until the relevant Joint Patent Right is filed or the
Parties determine not to file such Joint Patent Right, and thereafter, either Party may use or license or sublicense to Affiliates or Third Parties all or any portion of its interest in Joint Technology or Joint Patent Rights for any purposes inside
or outside of this Agreement, without the prior written consent of the other Party, without restriction and without the obligation to provide compensation to the other Party. For purposes of clarity, Article 8 shall not apply to the information or
data contained in the Joint Technology after the termination of this Agreement in any case. 
 10.5 Patent Filing and
Prosecution. 
 10.5.1 Patent Coordinators. Each Party shall appoint a patent coordinator reasonably acceptable to the
other Party (each, a “Patent Coordinator”) to serve as such Party’s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement under this Agreement.
Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party. 

  
 47 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 10.5.2 Characterization of Program Technology. DICERNA and KHK shall discuss
and attempt to resolve in good faith on a case by case basis as to how all Program Technology made in the conduct of the Research Collaboration should be categorized (i.e., whether it should be characterized as DICERNA Program Technology, KHK
Program Technology or Joint Technology). If DICERNA and KHK are unable to agree upon the appropriate proper categorization of Program Technology, the Parties may jointly appoint a neutral patent expert (patent counsel who (and whose firm) is not at
the time of the dispute, and was not at any time during the [***] prior to such dispute, performing services for either of the Parties) reasonably acceptable to the Parties to mediate their discussions and help resolve the issue. Any such dispute
shall be resolved according to U.S. patent law. The Parties shall share the costs and expenses of any such neutral patent expert. 
 10.5.3
Joint Patent Rights. The Parties will determine which Party will undertake the preparation, filing, prosecution, maintenance and enforcement of Joint Patent Rights based on the respective expertise of the Parties. If the Parties fail
to agree, then prosecution of such Joint Patent Rights shall be jointly controlled by the Parties, using patent counsel agreed upon by the Patent Coordinators of both Parties. The patent costs incurred in connection with the preparation, filing,
prosecution, maintenance and enforcement of Joint Patent Rights will be shared equally by the Parties. 
 10.5.4 DICERNA
Filings. DICERNA or City of Hope, as the case may be, shall have sole right, at its sole discretion and at DICERNA’s sole expense, to prepare, file, prosecute, maintain and enforce the DICERNA Background Dicer Substrate Patent Rights,
DICERNA Background DDS Patent Rights, DICERNA KRAS-Specific Patent Rights and DICERNA Program Patent Rights. 
 10.5.5 KHK
Filings. KHK shall have sole right, at its sole discretion and at KHK’s sole expense, to prepare, file, prosecute, maintain and enforce the KHK Background Patent Rights and KHK Program Patent Rights. 

10.5.6 Information and Cooperation. Each filing Party shall (a) discuss with the other Party, through the Patent
Coordinator, the filing of any patent application with respect to any Program Technology; (b) regularly provide the other Party with copies of all patent applications filed hereunder for any Program Technology and other material submissions and
correspondence with the patent offices, in sufficient time to allow for review and comment by the other Party; (c) provide the other Party and its patent counsel with an opportunity to consult with the Party and its patent counsel regarding the
filing and contents of any such application, amendment, submission or response, and the advice and suggestions of the other Party and its patent counsel shall be taken into consideration in good faith by such

  
 48 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Party and its patent counsel in connection with such filing; and (d) execute any documents that may be necessary to perfect the filing Party’s rights in and to any Program Technology
and, in the event that the filing Party is unable for any reason to secure the signature of the other Party to any lawful and necessary document required to perfect its rights in and to any such Program Technology, the other Party hereby designates
the filing Party as its agent, and hereby grants to the filing Party a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the sole purpose of effecting the foregoing. Each filing
Party shall pursue in good faith all reasonable claims requested by the other Party in the prosecution of any Patent Rights under this Section 10.5.6. 

10.5.7 Election Not to File, Prosecute or Maintain. If the responsible Party under this Section 10.5 elects (a) not to
file a patent application claiming any Program Technology in a particular country, or (b) to discontinue prosecution or maintenance of any Patent Right with respect to Program Technology controlled by such Party, that Party (the
“Initial Responsible Party”) shall give [***] advance written notice to the other Party of any decision to cease preparation, filing, prosecution and maintenance of that Patent Right (a “Discontinued
Patent”); provided, however, that abandonment of a patent application in favor of a continuation or a continuation-in-part thereof shall not constitute discontinuance of the patent application. In such case, the other Party may elect at
its sole discretion to continue preparation, filing, prosecution or maintenance of the Discontinued Patent at its sole expense. The Party so continuing shall own any such patent application and patents maturing therefrom and be solely responsible
for all costs, and the Initial Responsible Party shall have a non-exclusive, worldwide, irrevocable, perpetual, fully-paid license to continue to practice such Discontinued Patent, including the right to
sublicense, as provided under this Agreement. In addition, such Party so continuing shall cease to have any obligation to pay royalties to the Initial Responsible Party under this Agreement with respect to the Discontinued Patent. The Initial
Responsible Party shall execute such documents and perform such acts as may be reasonably necessary for the other Party to file or to continue prosecution or maintenance, including assigning ownership of such patents and inventions to such electing
Party. Discontinuance may be on a country-by-country basis or for a patent application or patent series in total. 
 10.5.8 Patent
Term Extensions. The Parties shall cooperate with each other in gaining patent term extension wherever applicable to any Licensed Product. All filings for such extension shall be made by the Party to whom the responsibility for prosecuting
patent is assigned; provided, however, that in the event that the Party to whom the responsibility for such patent is assigned elects not to file for an extension, such Party shall (a) inform the other Party of its intention not to file,
(b) grant the other Party the right to file for such extension, and (c) cooperate as necessary to assist the other Party in filing such extension. 

  
 49 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 10.6 Infringement Claims Against Third Parties. 

10.6.1 Notice. Each Party shall notify the other Party if it becomes aware of a patent
infringement or the like by a Third Party of any Patent Rights the prosecution of which is controlled by a Party covering or relating to a Licensed Product (each, an “Infringement”). The Parties shall mutually discuss what
action to take with respect to such Infringement. 
 10.6.2 DICERNA Right to Enforce. DICERNA or City of Hope,
as the case may be, shall have the first right, but not the obligation, upon written notice to KHK, to take appropriate action to address any such Infringement that involves DICERNA Background Dicer Substrate Patent Rights, DICERNA Background DDS
Patent Rights, DICERNA KRAS-Specific Patent Rights or DICERNA Program Patent Rights by taking reasonable steps, which may include the institution of legal proceedings or other action (an “Action”), and to
compromise or settle such Action; provided, that, (a) DICERNA shall keep KHK fully informed about such Action and KHK shall provide reasonable cooperation to DICERNA in connection with such Action; (b) if neither DICERNA nor City of Hope
intends to prosecute or defend an Action, or ceases to diligently pursue such an Action, DICERNA shall promptly inform KHK in such a manner that such Action will not be prejudiced and Section 10.6.3 shall apply; (c) no settlement with
respect to DICERNA Program Patent Rights or Joint Patent Rights shall be entered into by DICERNA without the prior written consent of KHK if such settlement would reasonably be expected to adversely affect or diminish the rights and benefits of KHK
under this Agreement with respect to the Licensed Products and (d) DICERNA shall not be entitled to settle any such Action granting a license or covenant not to sue under or with respect to DICERNA Program Patent Rights or Joint Patent Rights
that is reasonably likely to directly and adversely affect the scope, validity or enforceability of the KHK Program Patent Rights or that would be inconsistent with the license and other rights granted to KHK hereunder without the prior written
consent of KHK, which consent shall not be unreasonably withheld. All costs, including attorneys’ fees, relating to any such Action undertaken by DICERNA shall be borne by DICERNA. 

10.6.3 KHK Right to Enforce. KHK shall (a) have the first right (but not the obligation, upon written notice to DICERNA, to
take appropriate action to address any Infringement that involves KHK Program Patent Rights and (b) shall have the right, but not the obligation upon written notice to DICERNA, to take appropriate action to address any Action DICERNA determines
not to pursue under Section 10.6.2; provided, that, (i) KHK shall keep DICERNA fully informed about such Action and DICERNA shall provide reasonable 

  
 50 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
cooperation to KHK in connection with such Action; (ii) KHK shall not take any position with respect to, or compromise or settle, such Action in any way (including by granting a license or
covenant not to sue) that would reasonably be expected to adversely affect the scope, validity or enforceability of the DICERNA Background Dicer Substrate Patent Rights, DICERNA Background DDS Patent Rights, DICERNA Program Patent Rights or Joint
Patent Rights without DICERNA’s prior written consent, which consent shall not be unreasonably withheld. All costs, including attorneys’ fees, relating to such Action undertaken by KHK shall be borne by KHK. 

10.6.4 Right to Representation. Each Party shall have the right to participate and be represented by counsel that it selects, in
any Action instituted under Section 10.6.2 or 10.6.3 by the other Party. If a Party with the right to initiate an Action under Section 10.6.2 or 10.6.3 to eliminate an Infringement lacks standing to do so and the other Party has standing
to initiate such Action, then the Party with the right to initiate an Action under Section 10.6.2 or 10.6.3 may name the other Party as plaintiff in such Action or may require the Party with standing to initiate such Action at the expense of
the other Party. 
 10.6.5 Cooperation. In any Action instituted under Section 10.6.2 or 10.6.3, the Parties shall
cooperate with and assist each other in all reasonable respects. Upon the reasonable request of the Party instituting such Action, if necessary to maintain such Action, the other Party shall join such Action and shall be represented using counsel of
its own choice, at the requesting Party’s expense. 
 10.6.6 Allocation of Proceeds. Any amounts recovered by either
Party pursuant to Actions under Sections 10.6 with respect to any Infringement, whether by settlement or judgment, shall, after reimbursing KHK and DICERNA (and/or City of Hope, as the case may be) for their reasonable internal costs and
out-of-pocket expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses), shall, with respect to Licensed Products that are not Co-Promoted Products, be retained by, or paid
to, as applicable, KHK and treated as Net Sales of the Licensed Product affected by the Infringement for purposes of this Agreement and, with respect to Co-Promoted Products, be allocated between the Parties as provided in the Co-Promotion
Agreement. Notwithstanding the foregoing, any recovery obtained by City of Hope as the result of any Action initiated by and paid for City of Hope shall be for the sole benefit of City of Hope. 

10.7 Defense of Infringement Claims. 

10.7.1 Notice. In the event that any action, suit or proceeding is brought against either Party alleging the infringement of the
Technology or Patent Rights of a Third 

  
 51 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Party by reason of or the development or commercialization, including the manufacture, use or sale, of any Licensed Product by or on behalf of KHK or any of its Affiliates or Sublicensees in the
Field and in the Territory, such Party shall notify the other Party within [***] and the Patent Coordinators shall meet as soon as possible to discuss the overall strategy for defense of such matter. 

10.7.2 DICERNA Right. In the event that any action, suit or proceeding brought against either Party or any Affiliate or
Sublicensee (with respect to KHK) or (sub)licensee (with respect to DICERNA) alleges the infringement of the Technology or Patent Rights of a Third Party by reason of the use of DICERNA Background Dicer Substrate Patent Rights or DICERNA Program
Patent Rights as provided in this Agreement (each, a “Dicer Substrate Infringement Action”), DICERNA shall have the right, but not the obligation, to defend such action, suit or proceeding at its sole cost and
expense; and KHK or any of its Affiliates or Sublicensees shall have the right to join with separate counsel at its own expense in any such action, suit or proceeding; and the Parties shall cooperate with each other in all reasonable respects in any
such action, suit or proceeding. 
 10.7.3 KHK Right. In the event that (a) DICERNA informs KHK that it does not intend
to defend any Dicer Substrate Infringement Action as set forth in above Section 10.7.2, or (b) any action, suit or proceeding brought against either Party or any Affiliate or Sublicensee (with respect to KHK) or (sub)licensee (with respect
to DICERNA) alleges the infringement of the Technology or Patent Rights of a Third Party for any reason other than as described in Section 10.7.2: (i) KHK shall have the right, but not the obligation to defend such action, suit or
proceeding; (ii) DICERNA or any of its Affiliates or sublicensees shall have the right to join with separate counsel at its own expense in any such action, suit or proceeding; (iii) the Parties shall cooperate with each other in all
reasonable respects in any such action, suit or proceeding and (iv) to the extent the action, suit or proceeding is a Dicer Substrate Infringement Action, KHK shall have the right to offset [***] percent ([***]%) of all the costs and expenses
incurred by KHK in the defense of such Dicer Substrate Infringement Action against royalties or milestone payment amounts otherwise payable by KHK to DICERNA under this Agreement; provided, that, any payments made pursuant to this
Section 10.7.3 shall be subject to the royalty reduction limitations of Section 7.7.5. 
 10.7.4 In General. Each
Party shall promptly furnish the other Party with a copy of each communication relating to any alleged infringement of any Third Party Technology or Patent Rights as a result or in connection with the development or commercialization of any Licensed
Product in the Field and in the Territory that is received by such Party including all documents filed in any litigation. 

  
 52 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 ARTICLE 11 

TERM AND TERMINATION 

11.1 Term of Research Collaboration. The Research Collaboration shall become effective on the Effective Date and continue
until the expiration of the Research Collaboration Term.  
 11.2 Term of Agreement. This Agreement shall
commence on the Effective Date and shall continue in full force and effect, unless otherwise terminated pursuant to Section 11.2, (a) in the Co-Promotion Territory, if DICERNA has exercised its Co-Promotion Option with respect to a
Licensed Product, for as long as such Co-Promoted Product is being sold by either Party in the Co-Promotion Territory (the “Co-Promotion Term”) and (b) in each country outside of the Co-Promotion Territory,
on Licensed Product by Licensed Product and country by country basis, until the expiration of the applicable Royalty Term in such country. Upon the expiration of the Royalty Term or the Co-Promotion Term, as the case may be, as set forth in this
Section 11.2 on a country by country, Licensed Product by Licensed Product basis, the license rights granted hereunder for such Licensed Product in such country shall be converted to a perpetual, irrevocable and fully paid-up license. 

 11.3 Termination During the Research Collaboration Term. During the Research Collaboration Term, KHK may
terminate this Agreement without cause upon giving DICERNA [***] written notice. 
 11.4 Termination for Breach.
Either Party may terminate this Agreement by notice to the other Party at any time during the Term of this Agreement if the other Party is in material breach of one or more substantial and material obligations hereunder and has not cured such
material breach within [***] after notice requesting cure of the material breach or such longer period of time, not to exceed [***], as is required to cure such material breach as long as the breaching Party is proceeding in good faith to cure;
provided, however, that, in any case when a breach is alleged regarding the payment of money hereunder, the time period will be [***] and undisputed amounts must be paid prior to such time to avoid breach. To the extent that a Party prevails in a
lawsuit brought against the other Party for material breach of this Agreement, such prevailing Party shall be entitled to collect from the other Party reasonable attorneys’ fees and legal costs incurred in connection with such lawsuit. If the
non-breaching Party terminates this Agreement under this Section 11.4 following material breach by the breaching Party, each Party shall return to the other Party all of the other Party’s Confidential Information and all Proprietary
Materials received from the other Party during this Agreement, and each Party shall cease all use of the other Party’s Confidential Information and Proprietary Materials received from the other Party for any purpose except as otherwise
specifically provided herein.  

  
 53 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 11.5 Termination Upon Insolvency. Either Party may terminate this
Agreement upon notice to the other should the other Party become insolvent or file or consent to the filing of a petition under any bankruptcy or insolvency law or have any such petition filed against it which has not been stayed within [***] of
such filing. During the Term of this Agreement, all rights and licenses granted under or pursuant to this Agreement by KHK or DICERNA are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses
of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that, during the Term of this Agreement, the Parties, as licensees of such rights under this Agreement, will retain and
may fully exercise all of their rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding-by or against either Party under the U.S. Bankruptcy Code, the Party
hereto that is not a party to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in their
possession, will be promptly delivered to them (a) upon any such commencement of a bankruptcy proceeding upon their written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under
this Agreement, or (b) if not delivered under (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 

11.6 KHK Termination Without Penalty. After receiving the results of the Research Collaboration, if KHK determines at its sole
discretion not to proceed with the development of any Research Compounds for the Initial Target in accordance with this Agreement, KHK shall have a right to terminate this Agreement without any penalty upon giving DICERNA [***] written notice. 

11.7 DICERNA Termination. Except to the extent the following is unenforceable under the Applicable Laws of a particular
jurisdiction where a patent application with respect to any DICERNA Patent Rights is pending or a patent within any DICERNA Patent Rights is issued, DICERNA may terminate this Agreement immediately upon written notice to KHK in the event that KHK or
any of its Affiliates or Sublicensees Challenges any DICERNA Patent Right or assists a Third Party in initiating a Challenge of any DICERNA Patent Right. 

11.8 Effect of Termination Due to KHK Uncured Breach or KHK Termination Without Cause. If KHK terminates this Agreement
without cause (including under circumstances covered by Section 11.6), or DICERNA terminates this Agreement as a result of KHK’s uncured material breach, the following shall apply: 

(a) all Licensed Products shall be assigned to DICERNA exclusively and KHK shall (i) grant DICERNA licenses under all Patent Rights and
Technology Controlled by KHK solely to the extent necessary to enable DICERNA to continue to develop and commercialize Licensed Products, (ii) provide DICERNA with such data and information (including manufacturing and regulatory information,
and, if appropriate, the right to reference any DMFs) and shall provide to DICERNA copies of all regulatory filings, Drug Approval Applications and Registrations as may be reasonably required to perform the same and (iii) provide DICERNA at
cost, with all supplies of Research Compounds and Licensed Products in the possession of KHK or any Affiliate or contractor of KHK if such stock exists after the period set forth in below Section 11.8.(b); 

  
 54 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (b) [***] 

(c) all licenses and rights granted by DICERNA to KHK, including all licenses granted to KHK under Article 6, shall immediately terminate and
DICERNA shall no longer be subject to any obligations under Sections 3.9; and 
 (d) each Party shall promptly return all Confidential
Information and Proprietary Materials of the other Party that are not subject to a continuing license hereunder; provided, that, each Party may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose
of establishing the contents thereof and ensuring compliance with its obligations hereunder. 
 11.9 Effect of Termination Due to
DICERNA Uncured Breach. If KHK terminates this Agreement as a result of DICERNA’s uncured material breach, the following shall apply: 

(a) all licenses to DICERNA Background Dicer Substrate Patent Rights, DICERNA Program Patent Rights, and/or DICERNA Background DDS Patent
Rights in effect as of the effective date of such termination shall continue following such termination solely to enable KHK to continue to develop and commercialize Licensed Products being developed and/or commercialized by KHK as of the effective
date of such termination subject to the payment by KHK of any applicable milestone payments and royalty payments under this Agreement; provided, that, [***]; and 

(b) each Party shall promptly return any Confidential Information and Proprietary Materials of the other Party that are not subject to a
continuing license hereunder; 

  
 55 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
provided, that, each Party may retain one copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring
compliance with its obligations hereunder. 
 11.10 Surviving Provisions. Termination or expiration of this Agreement for any
reason shall be without prejudice to: 
 (a) survival of rights specifically stated in this Agreement to survive; 

(b) the rights and obligations of the Parties provided in Sections 4.3, 7.9, 9.5, 9.6, 9.7, 10.4, 10.5.2, 10.5.3, 11.8, 11.9,11.10, 11.11,
13.4, 13.5, 13.6, and 13.11, and Article 8 (including all other Sections or Articles referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 11.10; and 

(c) any other rights or remedies provided at law or equity which either Party may otherwise have. 

11.11 Limitation of Liability. No Party shall be liable to another for indirect, incidental, consequential or special
damages, including but not limited to lost profits, arising from or relating to any breach of this Agreement, regardless of any notice of the possibility of such damages. Nothing in this Section is intended to limit or restrict the indemnification
rights or obligations of any Party under Article 9. 
 ARTICLE 12 

PUBLICITY 
 12.1
Disclosure of Agreement. Subject to Section 8.2.2, neither Party to this Agreement may release or disclose any information to any Third Party regarding the terms or existence of this Agreement or the reasons for any termination
hereof, without the prior written consent of the other Party. Without limitation, this prohibition applies to press releases, educational and scientific conferences, quarterly investor updates, promotional materials, governmental filings and
discussions with public officials, the media, security analysts and investors. However, this provision does not apply to any disclosures regarding this Agreement or related information to Regulatory Authorities such as the FDA to the extent required
by Applicable Laws, including requests for a copy of this Agreement or related information by tax authorities. If any Party to this Agreement determines a release of information regarding the existence or terms of this Agreement is required by
Applicable Laws (including releases as may be required to be filed through the Securities Exchange Commission or other government agency), that Party will notify the other Party as soon as practicable and give the other Party as much detail as
possible in relation to the disclosure required and the Parties will cooperate with 

  
 56 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
respect to determining what information should actually be released. The Parties have agreed to the wording of a press release in connection with this Agreement as set forth in Schedule 8
attached hereto. Notwithstanding the above, DICERNA shall have the right, at its sole discretion, to issue a press release announcing its receipt of any milestone payment under this Agreement and KHK shall have the right, at its sole discretion, to
issue a press release announcing the subsequent achievement of milestones for clinical and commercial development for Licensed Products. 

12.2 Use of Names, Logos or Symbols. No Party hereto shall use the name, trademarks, logos, physical likeness, employee
names or owner symbol of any other Party for any purpose, including, without limitation, private or public securities placements, without the prior written consent of the affected Party, such consent not to be unreasonably withheld or delayed so
long as such use of name is limited to objective statements of fact, rather than for endorsement purposes. Nothing contained herein shall be construed as granting either Party any rights or license to use any of the other Party’s trademarks or
trade names without separate, express written permission of the owner of such trademark or trade name. 
 12.3
Publication. The Parties acknowledge and agree that scientific lead time is a key element of the value of the research to be performed under this Agreement. In order to ensure that scientific publications are strictly monitored to
prevent any adverse effect of premature publication, the JSC shall establish a procedure for publication review and approval and each Party shall first submit to the other Party an early draft of all such publications, whether they are to be
presented orally or in written form, at least [***] prior to submission for publication. The other Party shall review each such proposed publication in order to avoid the unauthorized disclosure of any Confidential Information and to preserve the
patentability of inventions arising from the research performed in the course of the Research Collaboration. If, within [***] following receipt of an advance copy of a Party’s proposed publication, the other Party informs such Party
(a) that its proposed publication contains the other Party’s Confidential Information, then such Party shall delete such Confidential Information from its proposed publication and/or (b) that its proposed publication contains Program
Technology, the publication of which could be expected to have a material adverse effect on any Program Patent Rights, then such Party shall at the election of the other Party, either (1) delete such Confidential Information from such
Party’s proposed publication or (2) delay such proposed publication sufficiently long to permit the timely preparation and filing of a patent application(s) on the information involved. If, within [***] following receipt of an advance copy
of a Party’s proposed publication, the other Party fails to approve of such Party’s proposed publication, then such proposed publication shall be regarded as denied by the other Party and shall not be published.  

  
 57 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 ARTICLE 13 

MISCELLANEOUS 
 13.1
Force Majeure. No Party will be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (except payment
obligations) when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including, but not limited to, fire, flood, embargo, war, acts of war (whether war be declared or not), insurrection,
riot, civil commotion, act of terrorism, strike, lockout or other labor disturbance, act of God or act, omission or delay in acting by any governmental authority or the other Party. The affected Party will notify the other Party of such force
majeure circumstances as soon as reasonably practical and take reasonable steps to cure or overcome the same and resume performance of its obligations hereunder. 

13.2 Assignment. This Agreement may not be assigned or otherwise transferred, nor, except as expressly provided
hereunder, may any right or obligations hereunder be assigned or transferred, by a Party without the written consent of the other Party; provided, that, either Party may, without such consent, assign this Agreement and its rights and obligations
hereunder to (a) any wholly-owned subsidiary in a manner such that the assignor (if it continues as a separate entity) shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder or
(b) any successor by merger or sale of substantially all of its business unit to which this Agreement relates, or in the event of its merger or consolidation or change in control or similar transaction. This Agreement shall be binding upon the
permitted successors and permitted assigns of the Parties. Any assignment not in accordance with this Section 13.2 shall be void. 

13.3 Severability. In the event that any of the provisions contained in this Agreement are held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties. The Parties will replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s), which, insofar as practical, implement the purposes of this Agreement. 

13.4 Notices. All notices or other communications which are required or permitted hereunder will be in writing and deemed to be
effective (a) on the date of delivery if delivered in person and written confirmation of delivery is provided, (b) on the date sent by facsimile or other electronic transmission, provided such receipt is verified, (c) on the day
following date of deposit with an overnight courier if a receipt confirming delivery by overnight courier is 

  
 58 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
provided, or (d) three (3) days after mailing if mailed by first-class certified mail, postage paid, to the respective addresses given below, or to another address as it will designate
by written notice given to the other Party. 
 If to KHK, to: 

Kyowa Hakko Kirin Co. Ltd. 

1-6-1, Ohtemachi, 
 Chiyoda-ku,
Tokyo, 
 100-8185 Japan 

Attention: Director, Business Development Department 

If to DICERNA, to: 
 480 Arsenal
Street 
 Building 1, Suite 120 

Watertown, MA 02472 
 Attention:
Martin D. Williams, Chief Business Officer 
 with a copy to: 

Mintz, Levin, Cohn, Ferris & Popeo, P.C. 

One Financial Center 
 Boston, MA
02111 
 Attention: John J. Cheney, Esq. 

13.5 Dispute Resolution. 

13.5.1 Disputes. In the event of any controversy or claim arising from or relating to any provision of this Agreement, or any
term or condition hereof, or the performance by a Party of its obligations hereunder, or its construction or its actual or alleged breach, the Parties will try to settle their differences amicably between themselves. All unresolved disputes arising
under or related to this Agreement shall be submitted to final and binding arbitration under the commercial arbitration rules of the International Chamber of Commerce (the “ICC”). The site of arbitration shall be Tokyo, if
KHK is the respondent, and Boston, if DICERNA is the respondent. The panel of arbitrators will be comprised of one arbitrator chosen by KHK, one by DICERNA and the third by the two so chosen. If either, or both, of KHK or DICERNA fails to choose an
arbitrator or arbitrators within [***] after receiving notice of commencement of arbitration or if the two arbitrators fail to choose a third arbitrator [***] after their appointment, then either or both Parties shall immediately request that the
ICC select the remaining number of arbitrators to be selected, which arbitrator(s) shall have the requisite scientific background, experience and expertise. 

  
 59 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 13.5.2 Additional Procedures. Either Party may apply to the arbitrators for
interim injunctive relief until the arbitration decision is rendered or the dispute is otherwise resolved. Either Party also may, without waiving any right or remedy under this Agreement, seek from any court having jurisdiction any injunctive or
provisional relief necessary to protect the rights or property of that Party pending resolution of the dispute pursuant to this Section 13.5. The arbitrators shall have no authority to award punitive or any other type of damages not measured by
a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees in connection with any such arbitration; provided, that, the non-prevailing Party shall pay the costs and expenses incurred by the
prevailing Party in connection with any such arbitration, including reasonable attorneys’ fees and costs. 
 13.5.3
Non-Disclosure. Except to the extent necessary to confirm an award or decision or as may be required by Applicable Laws, neither Party nor any arbitrator may disclose the existence or results of any arbitration without the prior
written consent of both Parties. In no event shall any arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute would be barred by the applicable New York statute of limitations. 

13.5.4 Termination of Agreement. In the event of a dispute involving the alleged breach of this Agreement (including, without
limitation, whether a Party has satisfied its diligence obligations hereunder), neither Party may terminate this Agreement until resolution of the dispute pursuant to this Section 13.5. 

13.5.5 Decision of Arbitrators. The decision of the arbitrators shall be the sole, exclusive and binding remedy between the
Parties regarding the determination of all disputes presented. Any monetary payment to be made by a Party pursuant to a decision of the arbitrators shall be made in United States dollars, free of any tax or other deduction. 

13.6 Choice of Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York and
the United States without reference to any rules of conflict of laws. 
 13.7 Entire Agreement. This Agreement (including all
Schedules and Exhibits hereto) constitutes the entire agreement between the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral. Any amendment
or modification to this Agreement shall be made in writing signed by both Parties. In the event of any conflict between the terms of this Agreement and the Research Collaboration Plan, the terms of this Agreement shall govern. 

  
 60 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 13.8 Headings. The captions to the several Articles and Sections hereof
are not a part of the Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 

13.9 Independent Contractors. It is expressly agreed that the Parties will be independent contractors and that the
relationship between the Parties will not constitute a partnership, joint venture or agency. No Party will have the authority to make any statements, representations or commitments of any kind, or to take any action, which will be binding on the
other Parties, without the prior consent of such other Parties. Members of the JSC and the JRC shall be and shall remain employees of KHK or DICERNA as the case may be. DICERNA shall not incur any liability for any act or failure to act by employees
of KHK, including members of the JSC or JRC who are employees of KHK. KHK shall not incur any liability for any act or failure to act by employees of DICERNA, including members of the JSC or JRC who are employees of DICERNA. 

13.10 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.  
 13.11
Special Covenant: City of Hope. [***]. 
 13.12 Waiver. The waiver by a Party hereto of any right
hereunder or the failure to perform or of a breach by another Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 

13.13 Jointly Prepared. This Agreement has been prepared jointly and shall not be strictly construed against either
Party. 
 13.14 Purposes and Scope. The Parties hereto understand and agree that the Research Collaboration is
limited to the activities, rights and obligations as set forth in this Agreement. Nothing in this Agreement shall be construed (a) to create or imply a general partnership between the Parties, (b) to make either Party the agent of the
other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties with respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other, (e) to create
any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct or implied licenses or any other right other than as expressly set forth herein. 

  
 61 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 13.15 Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

[The remainder of page intentionally left blank.] 

  
 62 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set
forth above. 
  

									
	DICERNA PHARMACEUTICALS, INC.	 		 	KYOWA HAKKO KIRIN CO. LTD.
					
	By:	 	 /s/ James C. Jenson
	 		 	By:	 	[***]
	Name:	 	 James C. Jenson
	 		 	Name:	 	[***]
	Title:	 	 President and CEO
	 		 	Title:	 	[***]

  
 63 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 AMENDMENT NO. 1 TO 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Amendment No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of
December 2, 2010 (the “Amendment Effective Date”) by and between DICERNA PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“DICERNA”), and KYOWA HAKKO KIRIN CO. LTD., a
corporation organized and existing under the laws of Japan (“KHK”). DICERNA and KHK are each hereafter referred to individually as a “Party” and together as the “Parties.” Capitalized
terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the RESEARCH COLLABORATION AND LICENSE AGREEMENT entered into as of December 21, 2009 (the “Original Agreement Effective
Date”), by and between DICERNA and KHK (the “Agreement”). 
 WHEREAS, the Parties desire to amend the terms
of the Agreement in order to clarify the understanding of the Parties with respect to the use and ownership of certain intellectual property to be used in certain research to be conducted under the Agreement and the terms applicable to the screening
and selection by KHK of a certain target as a [***]Target pursuant to the Agreement on the terms and subject to the conditions set forth herein; and 

WHEREAS, KHK has requested that [***] be included in the Research Collaboration as a [***] Target [***], subject to the payment by KHK of the
[***] applicable thereto set forth in Section 7.2.5 of the Agreement; and 
 WHEREAS, in connection therewith, the Parties have agreed
to amend Schedule 5-C of the Agreement to include [***] as a [***] Target in accordance with Section 4.1(c)(i) of the Agreement, which amended Schedule 5-C is attached hereto. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto,
intending to be legally bound, hereby agree as follows: 
 1. Amendments to Agreement. 

(a) The following new definitions are hereby included in Article 1 and the remaining definitions in Article 1 are hereby renumbered
accordingly: 
 “1.38 “DICERNA Background [***] Technology” means any Know-How Controlled by
DICERNA that relates to any [***] and that is used by DICERNA, or provided by DICERNA for use, in this Agreement. For purposes of clarity, DICERNA Background [***] Technology shall not include DICERNA Program Technology or DICERNA’s interest in
Joint Technology. For purposes of this definition only, “Controlled” means, with respect to any Know-How that DICERNA licenses from a Third Party, the ability of DICERNA to grant a sublicense to such Know-How without violating the
license agreement with, and without the payment by DICERNA of any additional consideration to, the Third Party licensor. 

  
 1 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 “1.60 “Feasibility Study” means the research
activities to be carried out by DICERNA and KHK with respect to [***] described in the Research Collaboration Plan attached hereto as Exhibit B. For purposes of clarity, the Feasibility Study shall not include the Target Confirmation Study.

 “1.64 “Feasibility Study Term” means the period beginning on the date of [***] and continuing
for a period of [***], unless mutually shortened or extended by the Parties. 
 “1.65 “Feasibility Study Success
Criteria” means the qualitative and/or quantitative required Criteria as described in Exhibit B applicable to [***] in order to determine whether to advance [***] to a Target Confirmation Study. 

“1.66 “KHK Background [***] Technology” means any Know-How Controlled by KHK that relates to any
[***] and that is used by KHK, or provided by KHK for use, in this Agreement. For purposes of clarity, KHK Background [***] Technology shall not include KHK Program Technology or KHK’s interest in Joint Technology. For purposes of this
definition only, “Controlled” means, with respect to any Know-How that KHK licenses from a Third Party, the ability of KHK to grant a sublicense to such Know-How without violating the license agreement with, and without the payment
by KHK of any additional consideration to, the Third Party licensor. 
 “1.67 “KHK Background [***]
Technology” means any Know-How Controlled by KHK that relates to any [***]. For purposes of clarity, KHK Background [***] Technology shall not include KHK Program Technology or KHK’s interest in Joint Technology. For purposes
of this definition only, “Controlled” means, with respect to any Know-How that KHK licenses from a Third Party, the ability of KHK to grant a sublicense to such Know-How without violating the license agreement with, and without the
payment by KHK of any additional consideration to, the Third Party licensor. 
 “1.68 “KHK Background [***]
Patent Rights” means any Patent Rights Controlled by KHK during the Term that contain one or more claims that cover KHK Background [***] Technology. For purposes of clarity, (a) KHK Background [***] Patent Rights shall not
include KHK Program Patent Rights, and (b) attached hereto as Schedule 4-B is a complete and accurate list of all KHK Background [***] Patent Rights Controlled by KHK as of the Amendment Effective Date. 

“1.69 “[***]” means [***]. 

“1.70 “Target Confirmation Study” means the research activities to be carried out by DICERNA and KHK
with respect to [***] described in the Research Collaboration Plan attached hereto as Exhibit C following the achievement by [***] of the Feasibility Study Success Criteria. For purposes of clarity, the Target Confirmation Study shall not
include the Feasibility Study. 

  
 2 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 “1.71 “Target Confirmation Study Criteria” means the
qualitative and/or quantitative required Criteria as described in Exhibit C for [***] applicable to the conduct of the Target Confirmation Study. 

“1.72 “Target Confirmation Study Term” means, with respect to [***], the period beginning on [***] and continuing
for a period of [***], unless mutually shortened or extended by the Parties. 
 “1.73 “Tertiary Field” means
human pharmaceutical use for the treatment of [***]. 
 (b) The definition of Field in Section 1.60 of the Agreement is hereby deleted
in its entirety and the following is hereby inserted in lieu thereof: 
 “1.60 “Field” means, collectively, the
Primary Field, the Secondary Field and the Tertiary Field. 
 (c) The following definitions in Sections 1.43 and 1.81, respectively, of the
Agreement are hereby amended as set forth below, by adding the respective underlined portions to each otherwise unchanged provision, as follows: 

“1.43 “DICERNA Program Technology” means (a) any Program Technology that (i) is not KHK Program
Technology and (ii) is conceived or first reduced to practice by employees of, or consultants to, DICERNA, alone or jointly with any Third Party, without the use in any material respect of any KHK [***] DDS Technology, KHK Patent Rights or
Joint Technology; and (b) any Program Technology, regardless of whether conceived or first reduced to practice by employees of, or consultants to, DICERNA, KHK, or jointly by both Parties, that relates to, or constitutes, DICERNA Background
Dicer Substrate Technology, DICERNA Background [***] Technology or DICERNA Background Dicer Substrate Patent Rights. 
 “1.81
“KHK Program Technology” means (a) any Program Technology that (i) is not DICERNA Program Technology and (ii) is conceived or first reduced to practice by employees of, or consultants to, KHK alone or jointly
with any Third Party, without the use in any material respect of any DICERNA Technology, DICERNA Patent Rights or Joint Technology; and (b) any Program Technology, regardless of whether conceived or first reduced to practice by employees of, or
consultants to, DICERNA, KHK or jointly by both Parties, that relates to or constitutes the KHK [***] DDS Technology, KHK Background [***] Technology, KHK Background [***] Patent Rights, KHK Background [***] Technology and/or KHK Background Patent
Rights. 

  
 3 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (d) The definition of Joint Technology in Section 1.77 of the Agreement is hereby
deleted in its entirety and the following is hereby inserted in lieu thereof: 
 “1.77 “Joint Technology” means
any Program Technology, other than DICERNA Program Technology or KHK Program Technology, that is (a) jointly conceived or reduced to practice by employees of, or consultants to, KHK and employees of, or consultants to, DICERNA,
(b) conceived or reduced to practice solely by employees of, or consultants to, a Party through the use in any material respect of any Technology or Patent Rights of the other Party or (c) a new composition of matter consisting of [***].
For purposes of clarity, Joint Technology includes, but is not limited to, (i) data and information obtained under the Research Collaboration and (ii) any Program Technology, other than DICERNA Program Technology or KHK Program Technology,
with respect to any [***].” 
 (e) The definition of Research Collaboration Plan in Section 1.109 of the Agreement is hereby
deleted in its entirety and the following is hereby inserted in lieu thereof: 
 “1.109 “Research Collaboration
Plan” means each written plan (a) describing the research activities to be carried out by the Parties during the Research Collaboration Term in conducting the Research Collaboration pursuant to this Agreement, and (b) setting
forth all Criteria applicable to each Research Compound that is part of such Research Collaboration. For purposes of clarity, the Research Collaboration Plan shall include the research activities to be carried out by DICERNA and KHK with [***] as
part of the Feasibility Study and Target Confirmation Study, as described on Exhibit B and Exhibit C attached hereto and incorporated herein by reference.” 

(f) Section 2.2(a) of the Agreement is hereby amended to read as follows, by adding the underlying portion to the otherwise unchanged
provision: 
 “(a) KHK [***] DDS Technology or KHK [***]Technology; 

(g) The following new Section 4.1(c)(iv) is hereby included in Section 4.1(c) of the Agreement: 

(iv) Feasibility Study; Target Confirmation Study. 

(A) Conduct of Feasibility Study. As soon as practicable following the payment by KHK of the applicable [***] as a
[***]Target pursuant to Section 4.1(c)(i), the Parties will initiate a Feasibility Study with [***] according to the Research Collaboration Plan attached hereto as Exhibit B. During the Feasibility Study Term, each Party shall use
Commercially Reasonable Efforts to conduct the research activities for which it is responsible in accordance with such Research Collaboration Plan. Without limiting the foregoing, the obligations of the Parties set forth in Sections 3.6.2
through 3.6.9 shall apply to each of the Parties in its conduct of such research activities. 
 (B) Conduct of Target
Confirmation Study. KHK shall have the right, in its sole discretion and at any time during the Feasibility Study Term, based on the applicable Feasibility Study Success Criteria and the results of the

  
 4 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 
Feasibility Study, to determine to proceed with a Target Confirmation Study with respect to [***] (the “Target Confirmation Research Activities”) by providing written
notice to DICERNA (the “Target Confirmation Study Notice”). As soon as practicable following the receipt by DICERNA of such Target Confirmation Study Notice, the Parties shall (1) prepare an amendment to the Research
Collaboration Plan to describe the additional research activities to be conducted and the additional Criteria applicable thereto and (2) promptly initiate such additional research activities. A brief outline of the currently contemplated
content of such research activity is attached hereto as Exhibit C, to be revised and completed in more detail by the Parties if KHK elects to proceed. Each Party shall use Commercially Reasonable Efforts to conduct such additional
research activities for which it is responsible in accordance with such Research Collaboration Plan, as so amended. Without limiting the foregoing, the obligations of the Parties set forth in Sections 3.6.2 through 3.6.9 shall apply to each of the
Parties in its conduct of such research activities. 
 (h) Section 4.1(c)(ii) of the Agreement is hereby renumbered as
Section 4.1(c)(ii)(A) and new Sections 4.1(c)(ii)(B),(C) and (D) are hereby added to Section 4.1(c)(ii) as follows: 

(B) [***]. 

(C) [***]. 

(D) Study Results. For purposes of clarity (a) the Parties hereby acknowledge and agree, in accordance with
Section 1.77, that (1) all data and information obtained or produced in the conduct of the Feasibility Study and/or the Target Confirmation Study (the “Study Results”) shall be jointly owned by the Parties and
(2) subject to subsection (b) below, neither Party shall cause or allow any Study Results to be published without the prior written consent of the other Party; and (b) notwithstanding anything to the contrary in Section 10.4,
Section 1.77 or subsection (D)(a) above, on and after the date on which [***] becomes a Waived Target pursuant to this Agreement, (1) DICERNA shall solely own the Study Results and have the sole right to use such Study Results for any and
all purposes, inside or outside of this Agreement, without restriction, (2) DICERNA shall be deemed to have granted KHK the right to use such Study Results solely for internal research purposes and (3) as between the Parties, DICERNA shall have
the sole right to publish such Study Results; provided, that, (i) any contribution of KHK to the Study Results shall be duly recognized and co-authorship shall be determined in accordance with customary industry standards and (ii) to the
extent that any such Study Results to be published contain any Confidential Information of KHK, including without limitation KHK [***] DDS Technology or KHK Program Technology, DICERNA shall obtain the prior written consent of KHK to such
publication. 

  
 5 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (i) Section 6.1 of the Agreement is hereby deleted in its entirety and the following is
hereby inserted in lieu thereof: 
  

	 	“6.1	Licenses to KHK. 

 (a) DICERNA hereby grants to KHK and its Affiliates a
royalty-bearing license to (i) DICERNA Background Dicer Substrate Patent Rights, DICERNA Background Dicer Substrate Technology, DICERNA Program Patent Rights, DICERNA Program Technology, DICERNA KRAS-Specific Patents, DICERNA Background [***]
Technology and DICERNA’s interest in Joint Technology and Joint Patent Rights and (ii) to DICERNA Background DDS Patent Rights and DICERNA Background DDS Technology, solely to the extent such DICERNA Background DDS Patent Rights (the
Patent Rights described in (i) and (ii) above being referred to collectively as the “DICERNA Patent Rights”) and such DICERNA Background DDS Technology (the Technology described in (i) and (ii) above being
referred to collectively as the “DICERNA Technology”) are selected by KHK for a Research Compound or Licensed Product, in any case, to the extent necessary to research, develop, make, have made, use, offer for sale, sell and
import Research Compounds and Licensed Products (A) in the Primary Field (with respect to Research Compounds and Licensed Products for the Initial Target, subject to the payment of the applicable fee herein), (B) in the Secondary Field
(with respect to Research Compounds and Licensed Products for the Initial Target, subject to the payment by KHK of [***]), (C) subject to the payment by KHK of all applicable payments required under this Agreement, including the payment of the
applicable Lead Transfer Milestone, in the Secondary Field (with respect to Research Compounds and Licensed Products for any [***] Target and [***] Target), and (D) subject to the exercise by KHK of its [***] Right pursuant to
Section 4.1(c)(ii)(C), in the Tertiary Field (with respect to Research Compounds and Licensed Products for the applicable [***] Target), in each case in the Territory. Such licenses shall (a) be exclusive for the Initial Target in the
Primary Field and in the Secondary Field, subject to the payment by KHK of [***], exclusive for the [***] Targets, the [***] Targets and the [***] Target in the Secondary Field and exclusive for the [***] Target in the Tertiary Field, other than
Waived Targets; provided, that, DICERNA shall, and hereby does, reserve all rights under DICERNA Patent Rights and DICERNA Technology necessary for it to undertake research as part of the Research Collaboration and to Co-Promote Co-Promoted
Products, and (b) include the right for KHK and its Affiliates to grant sublicenses to Third Parties in accordance with Section 6.2.” 

(b) Limited Research License to KRAS. DICERNA hereby grants to KHK a non-exclusive, royalty-free license to DICERNA Patent Rights and
DICERNA Technology solely for the purpose of having KHK conduct, and solely to the extent necessary for KHK to conduct, research in the Tertiary Field using KRAS DsiRNA (including without limitation the prototype KRAS 1.1 which has already been
provided by DICERNA to KHK) in the conduct of the Feasibility Study as set out in Exhibit B. 

  
 6 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (j) Section 6.3 of the Agreement is hereby deleted in its entirety and the following is
hereby inserted in lieu thereof: 
  

	 	“6.3	License to DICERNA. KHK hereby grants to DICERNA a nonexclusive, royalty-free license to KHK Background Patent Rights, KHK Background [***] Technology, KHK Background [***] Technology, KHK Background [***]
Patent Rights, KHK Program Patent Rights and KHK’s interest in Joint Technology and Joint Patent Rights solely for the purpose of and to the extent necessary for DICERNA to perform its obligations under this Agreement, including in order for
DICERNA to undertake research as part of the Research Collaboration and to Co-Promote Co-Promoted Products; provided, that, the foregoing shall not include a license to KHK [***] DDS Technology unless such KHK [***] DDS Technology is selected by KHK
for a Research Compound. 

 (k) A new Section 6.5 is hereby inserted in the Agreement: 

 

	 	“6.5	Negotiation Right. In the event that either Party desires to obtain an exclusive license to use any [***] that is included within Joint Technology or Joint Patent Rights for a purpose other than in
connection with a Research Compound or a Licensed Product, such Party shall provide written notice to the other Party, which notice shall identify the [***] and the proposed field of use. As promptly as possible following the delivery of such
notice, the Parties shall commence the negotiation in good faith of the terms under which the other Party would grant an exclusive license under its interest in the applicable Joint Technology and/or Joint Patent Rights to the notifying Party with
respect to the [***] and field of use identified in the notice, which negotiations shall continue for a period not to exceed [***] from the date of the notice. If the Parties are unable to reach agreement on the terms of any such exclusive license
on or before the expiration of such [***] negotiation period (as such period may be extended by mutual agreement of the Parties), the other Party shall have no further obligation to negotiate with the notifying Party with respect to the grant of
such exclusive license. 

 (l) A revised Schedule 5-C is hereby added to the Agreement in substantially the form of
Schedule 5-C attached hereto in substitution of the existing Schedule 5-C attached to the Agreement. 

  
 7 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 (m) A new Exhibit B is hereby added to the Agreement in substantially the form of
Exhibit B attached hereto. 
 (n) A new Exhibit C is hereby added to the Agreement in substantially the form of Exhibit
C attached hereto. 
 2. Press Release. The Parties have agreed to the wording of a press release in connection with the
execution and delivery of this Amendment as set forth in Exhibit 1 attached hereto. 
 3. Miscellaneous. The
Parties hereby confirm and agree that, except as amended hereby, the Agreement shall remain in full force and effect and is a binding obligation of the Parties. This Amendment may be executed simultaneously in two or more counterparts, each of which
shall be deemed an original. 
 [Remainder of page intentionally left blank.] 

  
 8 

 ***Text Omitted and Filed Separately with the Securities and Exchange 

Commission. Confidential Treatment Requested Under 
 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2 
  

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	DICERNA PHARMACEUTICALS, INC.	 		 	KYOWA HAKKO KIRIN CO. LTD.
					
	By:	 	 /s/ Martin D. Williams
	 		 	By:	 	[***]
	Name:	 	 Martin D. Williams
	 		 	Name:	 	[***]
	Title: 	 	 Senior Vice President,
	 		 	Title:	 	[***]
		 	 Chief Business Officer
	 		 		 	[***]

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]